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Abstract 
 
La sindrome di Aicardi-Goutières (AGS) è una rara malattia infantile di origine genetica, i pazienti 
AGS sono caratterizzati da: atrofia cerebrale, calcificazioni intracraniche ed elevati livelli di 
interferone-alfa nel liquido cerebro-spinale. Questa inappropriata produzione di IFNα può diventare 
deleteria, promuovendo l’innesco di una risposta autoinfiammatoria nel paziente. AGS è causata da 
mutazioni in alcuni geni che codificano per enzimi che metabolizzano o rilevano la presenza di acidi 
nucleici: TREX1, ognuna delle tre subunità (RNASIH2A, RNASIH2B, e RNASIH2C) del complesso 
enzimatico RNasi H2, SAMHD1, ADAR1 e MDA5. Molteplici evidenze sperimentali suggeriscono 
che gli acidi nucleici siano responsabili dell’attivazione di sensori dell’immunità innata. Pertanto, 
l’ipotesi più accreditata è che un accumulo di acidi nucleici endogeni non processati possa essere la 
principale causa della patologia, inducendo gli elevati livelli di IFNα nel liquido cerebro-spinale. 
Tuttavia, quale sia la natura e il meccanismo di accumulo di questi acidi nucleici resta ancora ignoto. 
Tra tutti i geni responsabili della sindrome di Aicardi-Goutières, è stato dimostrato che TREX1, 
ADAR1 e SAMHD1 possono interferire nel metabolismo dei retroelementi LINE1, sequenze di DNA 
che possono muoversi nel genoma tramite un intermedio a RNA.  Un’ipotesi plausibile è quindi che 
sia proprio l’accumulo di alcuni intermedi di retrotrasposizione una delle cause scatenanti della 
iperattivazione dell’immunità innata. Caratterizzare un possibile coinvolgimento del metabolismo dei 
retroelementi e in particolare di LINE1, nella sindrome di Aicardi-Goutières è l’obbiettivo a lungo 
termine di questo progetto. 
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Abstract 
 
Aicardi-Goutières syndrome (AGS) is a rare genetically heterogeneous disease that typically affects 
newborns and infants and AGS patients are characterized by cerebral atrophy, intracranial 
calcifications and elevated levels of IFNα in the cerebrospinal fluid (CSF). Such inappropriate 
activation of type I IFN can be detrimental to the host by promoting autoinflammatory responses. 
AGS  is caused by mutations in several genes encoding nucleic acids sensor or metabolizing enzymes: 
the 3′ exonuclease 1 (TREX1), any of the three subunits (RNASEH2A, RNASEH2B, and 
RNASEH2C) of the ribonuclease H2 (RNase H2) enzyme complex, the triphosphohydrolase encoded 
by SAMHD1, the adenosine deaminase acting on RNA 1 (ADAR1), or the RNA sensor melanoma 
differentiation associated protein 5 (MDA5). Strong evidence suggest that the accumulation of 
nucleic acids is responsible for triggering sensors of the innate immunity. Therefore, it is generally 
believed that an accumulation of unprocessed, endogenous nucleic acids could be the main 
pathogenic trigger of AGS, increased CSF IFNα levels. Among all the AGS-causing genes, TREX1, 
ADAR1 and SAMHD1 could affect the correct metabolism of LINE1 retroelements, DNA sequences 
able to move in the genome through an RNA intermediate. Then, a conceivable cause of innate 
immunity hyperactivation could be retrotransposition intermediates accumulation. To characterize a 
possible involvement of retroelements metabolism in the AGS pathogenesis is the long term goal of 
this project. 
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Aim of the thesis 
 
RNase H2 is a hetero-trimeric enzyme and represents the primary source of ribonuclease H activity 
in mammalian cells, the non-sequence-specific endonuclease cleavage of RNA in an RNA:DNA 
substrate. Mutations in the three RNase H2 subunits account for over 50% of Aicardi–Goutières 
syndrome (AGS) patients and the molecular mechanisms linking RNase H2 mutations to AGS 
pathology have not been elucidated yet. Identify the cellular roles of RNase H2 that can be related to 
the AGS pathogenesis, and their characterization is the main objective of this project.  
Among all the AGS-causing genes, TREX1, ADAR1, and SAMHD1 could affect the correct 
metabolism of LINE1 retroelements, the most active autonomous transposable elements in humans. 
Considering RNase H2 enzymatic activities, it can potentially regulate the mobility of endogenous 
L1 retroelements by degrading RNA:DNA hybrids formed during their replication. On the basis of 
this hypothesis, I started to investigate the effects of RNase H2 on L1 retrotransposition using a 
genetic assay in human cells silenced for one of the three RNase H2 subunits. I set up these assays to 
verify if RNase H2 inhibits the mobility of endogenous retroelements.  
During the first two years of my PhD, other researcher groups published contrasting results 
concerning RNase H2 and L1 mobility. Therefore, my work assumes most importance in order to 
clarify controversial RNase H2 roles responsible for AGS pathogenesis. In particular, Choi and 
colleagues obtained similar results respect to mine in terms of RNase H2 impact on L1 
retrotransposition, and they concluded that RNase H2 inhibits L1 mobility29. On the other hand, in 
Benitez-Guijarro et al. has been demonstrated that in the absence of RNase H2, L1 mobility decreases. 
Based on their results, they concluded that RNase H2 is necessary for endogenous L1 mobility30.  
Since all these data are obtained using a genetic assay, which can be influenced by many factors, we 
decided to continue this characterization, starting to look at endogenous L1 regulation. It would be 
really interesting to repeat these kinds of L1 endogenous evaluations considering the other AGS-
causing genes, and I began to extend this analysis to two known L1 retrotransposition inhibitors, 
ADAR1 and TREX1. To demonstrate that the dysregulation of L1 mobility is a common role of AGS 
related nucleic acid metabolizing enzymes, it became the long term objective of my PhD thesis. 
Furthermore, we are also working on the demonstration that L1 intermediates accumulation in AGS 
patient cells is responsible for the overproduction of IFNα and at the end for the onset of AGS. 
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Introduction 
 
Aicardi-Goutières syndrome 
 
Aicardi–Goutières syndrome (AGS) was first described in 1984 by two French pediatric neurologists 
Jean Aicardi and Françoise Goutières. They get into a case of a child of consanguineous parents, 
suffering from calcification of the brain basal ganglia and severe encephalopathy. That infant also 
had a chronic cerebrospinal fluid (CSF) lymphocytosis, and for that reason, the case was initially 
misdiagnosed as intrauterine viral infection, despite the serological assays failed to detect any trace 
of viruses in the patient1. 
 However, when a female sibling and then a brother of the child was affected by the same condition 
shortly after their birth, Aicardi and Goutières discarded the infection diagnosis and proposed an 
unidentified genetic disorder instead1,2. This drove Aicardi and Goutières to expand the set by 
searching for other patients who presented congenital viral infection-like symptoms, and in a short 
space of time, they moved from the recognition of the first AGS-causing gene (AGS1) in 2007, to the 
discovery of four genes responsible for the pathogenesis. AGS1 was the DNA exonuclease TREX1 
and AGS2-4 were genes encoding ribonuclease H2 subunits, RNaseH2B (AGS2), RNaseH2C 
(AGS3) and RNaseH2A (AGS4). A deeper analysis of AGS cases showed that in over 80% of 
families, there were biallelic mutations in one of these four genes. In contrast, for the remaining 20%, 
no mutations were found, so at least one further AGS-causing gene must be discovered.  
Type I IFNs play central roles in innate immunity, but overproduction of IFNα can lead to 
immunopathologies. IFNα in the CSF during gestation or soon after birth has been considered to be 
the most informative marker for the diagnosis of AGS2. Prenatal diagnosis of AGS, measuring IFNα 
of fetal blood or cerebrospinal fluid, has not been accomplished, considering that this procedure 
would be risky and speculative. Indeed, IFNα levels in cerebrospinal fluid of AGS patients were high 
at birth and declined during the following years3. More recently, an increased level of expression of 
IFN-stimulated genes (ISGs) in peripheral blood, a so called IFN signature, has been reported to be 
present at any age in almost all AGS patients1. Patients with RNaseH2B mutations are an exception 
because approximately 30% of them had no such upregulation of ISGs1. 
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Figure 1: Chilblain lesions and intracranial calcifications of AGS patients1. 
 
 
The incidence of AGS is very low, with approximately 500 affected families known worldwide, onset 
occurs before 3 and 7 months of age in most patients, and the death rate is estimated to be around 
30%4. Although AGS is rare, its clinical importance is exaggerated by the high chance that its 
symptoms and signs may be mistaken for a non-genetic congenital infection3.  
Radiologically, the disease was characterized by basal ganglia calcification, white matter 
abnormalities, and brain atrophy. These features, together with the later development of chilblain skin 
lesions, constitute ‘classical’ AGS phenotypes1,5(Figure1).  
There are two main forms of AGS, the neonatal and the later onset ones. The neonatal form is typically 
due to TREX1 mutations, and neurological abnormalities are manifest at birth or in the first following 
days. These patients present features that can suggest congenital viral infection but with negative 
serologic assay results. In the later onset form, instead, a normal development period precedes a sub-
acute regression with extreme irritability and sterile pyrexias, followed by loss of skills and slowing 
circumference growth. This last described form of AGS is associated with a prolonged course, low 
mortality, and the gene most implicated is RNaseH2B2.  
Since 2007 when Yanick Crow and his colleagues have identified the first AGS causing gene TREX1, 
due to the advent of the new sequencing technologies, they characterize mutation in seven different 
AGS-related genes: TREX1, RNaseH2A, RNaseH2B, RNaseH2C, SAMHD1, ADAR and 
IFIH1(MDA5)2,4 (Table 1). These seven genes encode proteins that are involved in nucleic acid 
metabolism/signalling. This observation, together with the increased interferon levels in CSF, defines 
AGS as an autoimmune disorder associated with the induction of a type I interferon response driven 
by improper endogenous nucleic acid accumulation6.  
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While there is significant phenotypic overlap in patients with these seven mutations, inflammation in 
certain tissues appears to be associated with mutations in some AGS genes but not others, and the 
molecular mechanisms behind each mutation and symptom remain a matter of study4.  
 
 
  Table 1: Summary of AGS causing genes and their functions2. 
 
 
Intracellular nucleic acids detection and type I IFNs response 
 
A fundamental function of the immune system is to distinguish self from non-self and initiate a 
specific response against only the latter. During the past decade, there has been rapid progress in 
understanding how the innate immune system accomplishes this self and non-self discrimination. The 
discovery of germline-encoded pattern-recognition receptors (PRRs) in the 1990s showed how innate 
immunity recognizes danger signals emanating from pathogen-associated molecular patterns 
(PAMPs). Importantly, these PAMPs must be essential to the microbes so they cannot readily mutate 
them to avoid PRRs detection.  
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Whereas bacteria and fungi possess microbe-specific structures for immune recognition that are 
absent in the host, viruses present a unique challenge because every component of a virion is made 
from the infected host cell. Most antiviral responses are initiated by nucleic acids innate immune 
receptors. On the one hand, viruses cannot replicate without their DNA or RNA genome, but on the 
other hand, DNA and RNA are among the most abundant macromolecules in all of our cells. 
Therefore, it has become increasingly evident that these same sensors that protect us from a viral 
infection can also drive human autoimmune diseases when endogenous nucleic acids inappropriately 
activate them, and Aicardi-Goutières syndrome is an example of that. Indeed, AGS is an autoimmune 
disorder associated with the induction of type I IFNs response driven by improper endogenous nucleic 
acid accumulation in the cytoplasm of patient cells4.  
While some PRR transmembrane receptors, named Toll-like receptors, detect nucleic acids within 
endosomes of specialized cells such as dendritic cells or B cells (TLR3, TLR7, TLR8, and TLR9), a 
distinct and complementary set of nucleic acid-sensing receptors reside in the cytosol of virtually all 
cells. This last category of cytosolic nucleic acid sensors plays a central role in the initiation of 
antiviral immunity, and also in AGS pathogenesis.  
The cytosolic RNA sensors retinoic acid–inducible gene 1 (RIG-I), and melanoma differentiation-
associated protein 5 (MDA5) helicases, known as RIG-I-like receptors (RLRs) detect structural 
features of viral RNA, that are scarce within host RNAs, and activate an antiviral response that 
includes the inducible production of type I IFNs. In particular, RIG-I binds to short double-stranded 
RNAs that contain 5’ tri or di-phosphates and long, double-stranded RNAs activate MDA5. The 
binding of virus-derived RNAs to RIG-I or MDA5 leads to a conformational change that facilitates 
the exposure of their active N-terminal domains and the consequent association with the 
mitochondrial adaptor protein MAVS7.  
 
Figure 2: cGAS-STING pathway activation. 
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The principal intracellular DNA sensor is the nucleotidyl transferase cGAS, which upon ligand 
binding, catalyzes the synthesis of the cyclic GMP-AMP dinucleotide (cGAMP) using ATP and GTP 
as substrates. This second messenger molecule cGAMP binds to and activates an endoplasmic 
reticulum protein, the adapter molecule stimulator of interferon genes (STING). The activation of the 
adaptor protein MAVS, for what concerns RNA sensors, or STING, in case of DNA sensing, leads 
to their re-localization and association with TANK binding kinase 1 (TBK1) and causes the 
recruitment of the interferon regulatory factor 3 (IRF3) and nuclear factor-kB (NF-kB). After 
translocation into the nucleus, IRF3 induces the transcription of type I IFNs and ISGs, while NF-kB 
induces the expression of pro-inflammatory cytokines7,8 (Figure 2). Innate immune cells such as 
macrophages and dendritic cells, produce IFNα, whereas non-immune cells, such as fibroblasts or 
epithelial cells, predominantly produce IFNβ. 
 
Figure 3: The canonical type I IFN signalling pathway9. 
 
Secreted IFNα and IFNβ bind the transmembrane IFNα receptors (IFNARs), composed of two 
subunits IFNAR1 and IFNAR2, present on near cells. In the canonical type I IFN-induced signalling, 
IFNAR activates and is phosphorylated by Janus kinase 1(JAK1) and tyrosine kinase 2 (TYK2). 
Phosphorylation of IFNAR by these kinases results in the recruitment and activation of signal 
transducer and activator of transcription 1 and 2 (STAT1 and STAT2). Phosphorylated STAT1 and 
STAT2 dimerize and translocate to the nucleus where they can control different gene expression 
programmes.  
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In particular, there are three main STAT complexes formed in response to type I IFNs:  
• IFN-stimulated gene factor 3(ISGF3) complex, built by STAT1, STAT2 and IFN-
regulatory factor 9 (IRF9) that binds to IFN-stimulated response elements (ISREs; 
consensus sequence TTTCNNTTTC) to activate classical antiviral genes; 
• STAT1 homodimers bind to gamma-activated sequences (GASs; consensus sequence 
TTCNNNGAA) to induce pro-inflammatory genes expression; 
• STAT3 homodimers bind to GAS sequences and indirectly suppress pro-inflammatory 
genes expression by the induction of unknown transcriptional repressors (Figure 3). 
Innate immune cells respond to type I IFNs by enhancing antigen presentation and the production of 
cytokine and chemokines. Type I IFNs also activate the adaptive immune system, promoting 
maturation and proliferation of lymphocytes9. Conversely, in case of an inappropriate antiviral 
immunity activation, a persistent type I IFNs exposure results in dendritic cell activation and loss of 
B and T cell tolerance leading to autoantibody production. The targets of these autoantibodies are 
ubiquitous self-antigens and antigen-antibody complexes deposition in the capillary bed, followed by 
local leucocyte activation that causes destructive tissue inflammation. This pathologic condition, 
characterized by a constitutive production of IFNs and an inflammatory response against self-tissues, 
is known as interferonopathy9,10 (Figure 4).  
 
 
 
Figure 4: Chronic IFN production in autoimmune diseases9. 
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The type I interferonopathies can be categorized into four main classes. The first class, represented 
by AGS, is caused by mutations in genes encoding enzymes that regulate intracellular nucleic acid 
accumulation that activate either cGAS-STING or RLR-MAVS pathways. The second class is 
induced by mutations that provoke an enhanced sensitivity or ligand-independent activation of cGAS-
STING or RLR-MAVS pathways. The third is represented by systemic lupus erythematosus (SLE)-
like diseases caused by the mutation in extracellular nucleases that activate TLRs. Finally, the last 
class is due to defects in pathways that modulate type I IFN responses independent of nucleic acid 
sensing4,7. Type I IFN activation induced by immune recognition of self nucleic acids is a key event 
in the pathogenesis of type I interferonopathies, excluding the fourth class. For that reason, the 
identification of the endogenous nucleic acid species involved in the cGAS-STING or RLR-MAVS 
activation, in the case of AGS, is of primary relevance. To characterize the nucleic acid species 
involved in AGS pathogenesis, the starting point is the study of the heterogeneous genetic basis of 
this syndrome.  
 
The genetic basis of AGS 
 
As mentioned before, AGS is a genetically heterogeneous disease resulting from mutations in any 
one of the genes encoding: the 3′ exonuclease 1 (TREX1), any of the three subunits (RNASEH2A, 
RNASEH2B, and RNASEH2C) of the ribonuclease H2 (RNase H2) enzyme complex, the tri-
phosphohydrolase encoded by SAMHD1, the adenosine deaminase acting on RNA 1 (ADAR1), or 
the RNA sensor melanoma differentiation associated protein 5 (MDA5; encoded by IFIH1)11 (Figure 
5,6). All these genes are deeply characterized, but the link with the unset of pathologies remains 
unclear. 
Figure 5: AGS-causing genes percentages. 
RNASEH2A
RNASEH2B
RNASEH2C
TREX1   
ADAR1   
SAMHD1   
MDA5   
24%   
7%   
13%   
3%   
53%   
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TREX1 
The DNA nucleases are involved in DNA replication, repair, and recombination and are essential to 
maintain genome stability. These enzymes can have endo or exonuclease activities, a selective affinity 
for single or double-stranded DNA (ssDNA or dsDNA) and hydrolyse in a 5’-3’ or 3’-5’ direction 
producing 5’ mono or di-nucleotides and 3’ mononucleotides. The 3’ repair exonuclease I (TREX1) 
is the most abundant DNA 3’-5’ exonuclease in mammalian cells12. TREX1 is a widely expressed 
homo-dimeric protein with no orthologues in lower eukaryotes, that preferentially degrades ssDNA. 
TREX1 shares homology to proof-reading DNA exonucleases in bacteria, but unlike the proof-
reading exonucleases, TREX1 is anchored by its C terminus to the cytosolic face of the ER membrane.  
Loss-of-function mutations of TREX1 in humans cause autoimmune diseases, including AGS, 
familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with 
cerebral leukodystrophy (RVCL)13. Similar to AGS, TREX1 ko mice have an elevated type I ISG and 
develop high levels of inflammation in multiple tissues, leading to significant mortality. Interestingly, 
TREX1 ko mice develop inflammatory myocarditis and lack detectable inflammation in the brain. 
Whereas, in humans, AGS affects the brain, but only rarely the heart and that difference in target 
tissues between TREX1 deficiency in humans and mice remain unclear4.  
To investigate the mechanism underlying the autoimmune diseases caused by TREX1 deficiency, 
Stetson and colleagues generated TREX1 ko mice lacking IRF3, IFNAR, or RAG2, a DNA 
recombinase required for the generation of functional lymphocytes14. In each case, the mortality and 
cardiac inflammation observed for just TREX1 ko mice were nearly completely rescued. These 
results provide evidence that the activation of the IRF3 pathway is responsible for the autoimmune 
diseases caused by TREX1 loss of function mutations, at least in mice15,14. In the last years, they 
farther demonstrated that the accumulated endogenous DNAs in TREX1 null mice activate the cGAS-
STING pathway16.  
Given that TREX1 is a DNA nuclease, a reasonable hypothesis is that cells lacking this enzyme 
accumulate DNA that activates the cGAS-STING pathway. The studies of TREX1 ko mice showed 
an accumulation of ssDNA in the endoplasmic reticulum in MEFs and of cytosolic DNA in mice 
hearts respect to wild type once. Although the nucleic acid sensors involved in TREX1 autoimmune 
diseases have been identified, it remains to clarify the source of these accumulated endogenous DNA 
molecules15,14. There are at least three main sources that are not mutually exclusive.  
The first possibility is those TREX1 substrates derived from retroelements. Supporting this 
possibility, in mice, overexpression of TREX1 inhibited the retrotranscription and integration of two 
synthetic retroelements, LTR and LINE14,15,14. Moreover, it is observed abundant extrachromosomal 
DNA in human pluripotent stem cells lacking TREX1 respect to control cells, of which endogenous 
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LINE1 was a major source17,18. However, retroelement-derived DNA may not be the only substrate 
metabolized by TREX1; a second possibility is that this enzyme eliminates DNA by-products of DNA 
replication or repair. Indeed, Yang et al. found that TREX1 deficient MEFs had cell-cycle defects 
resulting from chronic activation of a DNA-damage checkpoint4,19. A third possibility is that TREX1 
regulates inflammation independent of its DNA exonuclease activity. Supporting this hypothesis, in 
Peng Li et al., it is reported a nuclease-independent involvement of TREX1 in preventing LINE1 
retrotransposition. In particular, TREX1 interacted with LINE1 ORF1 protein triggering its depletion 
and causing at the end, according to their model, reduced LINE1-mediated nicking of genomic 
DNA4,20.  
RNase H2 
Ribonuclease H2 (RNase H2) belongs to the family of RNase H enzymes, that process the RNA 
moiety of RNA:DNA hybrid molecules. These hybrids are physiological intermediates produced 
during multiple cellular processes, such as retroviral infection, retroelement mobilization, during the 
synthesis of Okazaki fragments, and when a replication fork collides with the transcriptional 
machinery. Besides cleaving the RNA moiety of a plain RNA:DNA hybrid, RNase H enzymes 
participate in the removal of ribonucleotides embedded in a DNA duplex. Two classes of RNases H, 
with partially overlapping substrate specificity, have been characterized, RNase H1 and RNase H221.  
Mammalian RNase H1 has two isoforms: a nuclear isoform of undefined function and a mitochondrial 
one that, probably due to its ability to hydrolyse RNA:DNA hybrids, is essential for mitochondrial 
DNA replication and maintenance22.  
RNase H2 is a trimeric enzyme conserved in all eukaryotes, and it’s the major source of ribonuclease 
H activity in mammalian cells. This protein complex is composed of three subunits designated as A, 
B, and C. RNase H2A contains the catalytic center and forms a complex with RNase H2B and H2C 
subunits, which presumably fulfill accessory functions by serving as docking platforms for 
intracellular binding partners. Mutations in RNase H2 account for over 50% of AGS patients, and the 
molecular mechanisms linking RNase H2 mutations to AGS phenotypes have not been elucidated 
yet. RNase H2, besides being able to process long RNA:DNA hybrids, has the unique property of 
cleaving single ribononucleotide triphosphates (rNMPs) embedded in genomic DNA, as opposed to 
RNase H1 that requires at least four consecutive ribonucleotides embedded in a dsDNA sequence to 
cleave21,22. DNA polymerases can distinguish between rNTPs and dNTPs and select the latter during 
DNA replication. However, the fidelity of DNA polymerases is challenged by the high ratio of rNTPs 
respect to dNTPs that ranges from 10- to 100-fold in mammalian cells, and rNTPs are mis-
incorporated into genomic DNA with high frequency during normal replication.  
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Stable incorporation of rNTPs in DNA it is usually avoided because it makes DNA prone to strand 
breakage and mutagenesis22,23. Recent studies from our and other groups have attributed a critical 
role to RNase H2 in preserving genome integrity by controlling genomic rNTPs incorporation during 
DNA replication21,24,25,26. Complete RNase H2 deficiency in mice is embryonic lethal at the 
gastrulation stage of development. This lethality is caused by defective removal of rNTPs from 
replicating genomic DNA, which results in massive genome instability and p53-dependent DNA 
damage response leading to apoptosis. The evidence that RNase H2 deficiency in mammals is not 
compatible with life, in contrast to what happens in a unicellular organism like yeast and bacteria, is 
consistent with the fact that only hypomorphic RNase H2 mutations have been reported in AGS 
patients4,23,26. 
Probably due to the early lethality, RNase H2 ko mice do not show a systemic type I interferon 
signature. Instead, two recently generated knock-in mice that express RNase H2A and H2B AGS 
mutations have an interferon signature, and this type I IFN production is cGAS and STING 
dependent. The nature of the immunostimulatory nucleic acids accumulated in RNase H2-deficient 
cells triggering cGAS activation, remains undefined. Some evidence suggests that cGAS-STING 
activation is related to the accumulation of DNA repair byproducts caused by genomic rNTPs 
incorporation4,27,28. Another possible source of immunostimulatory nucleic acids in RNase H2 
deficiency condition can be endogenous retroelements intermediates. RNase H2 may regulate the 
mobility of endogenous retroelements by degrading RNA:DNA hybrids formed during their 
replication. Choi et al. and my data indicate that RNase H2 knockdown in different human cell lines 
seems to cause an increase in LINE1 retrotransposition efficiency29. Unexpectedly, another researcher 
group published opposite results by setting up retrotransposition assays on RNase H2A KO HeLa 
cellular clones30. Further work is needed to establish the exact RNase H2 involvement in the LINE1 
retrotransposition process, and in general, to characterize the nature of accumulated nucleic acids that 
trigger cGAS-STING activation leading to IFNα production.  
SAMHD1 
Both prokaryotes and eukaryotes have developed defence mechanisms to protect their cells from viral 
invasions. In addition to innate and adaptative immune responses, an intrinsic antiviral system based 
on constitutively expressed intracellular proteins, known as restriction factors, are emerging. These 
restriction factors act during the first steps of virus-host interactions, and viral proteins often 
counteract them. Among known intrinsic restrictor factors, there are: APOBEC3 class of cytidine 
deaminases, components of nuclear domain structures, DNA repair proteins and viral capsid 
inhibitors.  
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Recently, the uncharacterized human sterile alpha motif (SAM) domain and histidine-aspartate (HD) 
domain-containing protein 1 (SAMHD1) has been shown to be a novel restriction factor that inhibits 
replication of HIV-1 genome in myeloid cells31. SAMHD1 is a deoxynucleoside triphosphate 
(dNTPs) hydrolase that depletes intracellular dNTP pools in non-cycling cells. It has been proposed 
that SAMHD1 inhibits HIV-1 infection by depleting the dNTP pools required for reverse transcription 
of the viral RNA genome32,33,34.  
17% of AGS cases is caused by biallelic loss-of-function mutations of SAMHD1. SAMHD1 ko mice 
show a chronic induction of type 1 IFNs in a cGAS and STING dependent manner. Like other AGS 
genes, the identity of the immunostimulatory nucleic acids accumulated in SAMHD1 depleted cells 
remains completely undefined35,36.  
Zhao et al. demonstrated that several domains of SAMHD1 are critical for its inhibition of LINE1 
retrotransposition in dividing cells37. SAMHD1 ability to block LINE1 retrotransposition suggests 
that retroelement cDNA can be a source of cGAS ligands. Interestingly, it seems that SAMHD1 
regulates retroviruses and retrotransposons through different mechanisms. In fact, SAMHD1 inhibits 
HIV infection in just non-dividing cells and inhibits LINE1 mobility in dividing cells. In G1, 
SAMHD1 is dephosphorylated by the PP2A-B55α phosphatase, it forms a tetramer and acts as a 
dNTP hydrolase to inhibit HIV infections. Upon entry in S phase, phosphorylation by Cyclin A-
CDKs leads to the dissociation of SAMHD1 tetramers compromising its enzymatic activity and 
antiviral potency without interfering with LINE1 inhibition38. Furthermore, phosphorylated 
SAMHD1 is recruited to DNA repair foci in response to DNA damage, where it binds with high 
affinity RPA, fork structures, and MRE11, promoting an MRE11-dependent resection at stalled 
replication forks. ssDNA accumulated at stalled forks recruits the checkpoint kinase ATR, which in 
turn activates CHK1 to promote fork restart. In human SAMHD1 depleted cells, ssDNA fragments 
are displaced from stalled forks by RECQ1 DNA helicase, cleaved by MRE11, and accumulated in 
the cytosol. These replication stress byproducts can activate the cGAS-STING pathway to induce 
innate immunity activation39,40.  
ADAR1 
Adenosine deaminases that act on RNA (ADARs) are RNA editing enzymes that target double-
stranded regions of nuclear-encoded and viral RNAs and catalyse the deamination of adenosine to 
produce inosine. Hypoxanthine, the base of the nucleotide inosine generated by the editing process, 
is recognised as guanine by the translational and transcriptional machinery, so ADAR proteins change 
the primary sequence information in an RNA potentially leading to functional alterations of the 
affected genes. In addition, the I-U base pair is unstable compared to the parental A-U base pair, and 
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consequent changes in the secondary structure of RNA can result in its degradation. In general, 
ADARs have been shown to affect the splicing rate, the translational efficacy, or the stability of the 
edited mRNAs41.  
Among ADAR proteins, in 2012, AGS mutations in ADAR1 have been identified42. ADAR1 is 
widely expressed during embryonic and postnatal development in its constitutive and predominantly 
nuclear p110 isoform. An additional IFN inducible ADAR1 isoform, the p150 one, is found in both 
nucleus and cytoplasm of mammalian cells43. ADAR1 deficiency in mice results in hematopoietic 
failure and massive type I IFN signature before embryonic lethality. Several mechanisms have been 
proposed to explain these severe phenotypes of ADAR1 ko mice44. Pestal et al. demonstrate that 
ADAR1 is an essential negative regulator of the MDA5-MAVS RNA sensing pathway. In particular, 
they show that ADAR1 p150 isoform, the only one mutated in AGS patients, regulates the MDA5 
pathway, whereas both the p150 and p110 isoforms contribute to development45.  
It remains to identify the RNA ligands of MDA5 that are edited by ADAR1. Approximately half of 
the mammalian genome is composed of retrotransposons, which typically form dsRNAs that are 
subjected to extensive A-to-I editing. Retrotransposons located in 3’UTR regions can be accumulated 
in the cytoplasm triggering MDA5 pathway activation. Based on these considerations, it is proposed 
that ADAR1 editing of retrotransposons dsRNA prevents MDA5 activation. Conversely, in ADAR1 
deficiency conditions, retrotransposons can form long dsRNA stem-loops that can be recognised by 
MDA546.   
Alu retroelements that are the most abundant and active retrotransposons, with more than 1 million  
copies in the human genome, have been proposed to be the primary targets of ADAR146.  
In Orecchini et al., it is reported a possible ADAR1 LINE1 inhibitory function that is independent of 
its editing activity47. LINE1s can retrotranspose not only a copy of their RNA but also other RNAs, 
such as Alu elements48. Therefore, in AGS patients carrying ADAR1 mutations, non-edited Alu 
elements RNA widespread by LINE1 could trigger an MDA5 dependent IFN overproduction.  
IFIH1/MDA5 
The interferon-induced with helicase C domain 1 (IFIH1), also known as melanoma differentiation-
associated protein 5 (MDA5), is a cytoplasmic viral RNA RIG-I-like receptor (RLR). Either RIG-I, 
and MDA5 RLR members are RNA helicases that bind to dsRNA; however, RIG-I seems to ‘prefer’ 
short dsRNA, whereas MDA5 can specifically bind long dsRNA. When bound to dsRNA, MDA5 
forms a closed ring structure around the dsRNA stem leading to a conformational change that 
facilitates the exposure of its N-terminal domains that activate the adaptor protein MAVS located on 
the mitochondrial outer membrane.  
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Oligomerization of MAVS induces TBK1 activation, IRF3 phosphorylation, and initiation of 
signalling cascades that induce the expression of cytokines, including type I IFNs7.  
The previously described studies about TREX1, RNase H2 complex, SAMHD1, and ADAR1 AGS-
related proteins suggest that an inappropriate accumulation of self-derived nucleic acids can induce 
type I IFNs production. The finding of AGS mutations in the IFIH1 gene implicates the aberrant 
sensing of nucleic acids as a cause of hyperactivation of innate immunity. AGS-causing mutations in 
the IFIH1 gene are the last identified and are the only known gain-of-function mutations in this 
disease; these mutants bind dsRNAs more avidly and tightly than wild-type. The precise nature of 
dsRNA species that can stimulate the mutant, but not wild-type MDA5 remains unknown4,49. 
Although the nature of such nucleic acid ligands is unknown, one may speculate that they could be 
derived from retroelements.  
 
 
 
 
Figure 5: Cytosolic nucleic acids triggers IFNs production through cGAS-STING or RIG1-MDA5 pathways.  
               Red arrows indicate AGS-causing genes. (Adapted from Yanick J. Crow and Nicolas Manel, 2015) 
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RNase T2, a putative AGS gene 
 
The RNase T2 is the only member of the Rh/T2/S glycoprotein family in humans. This protein family 
of acid hydrolases is widely distributed in organisms from viruses to humans. RNase T2 is an ssRNA 
extracellular ribonuclease with a preferential cleavage of poly-A and poly-U of homo-
polyribonucleotides. RNase T2 is involved in the pathogenesis of several human neoplasias such as 
ovarian cancer, melanoma, and non-Hodgkin lymphoma. In ovarian cancer models, the onco-
suppressive role of this protein is associated with the recruitment of macrophages into the tumour 
mass50.  
Several RNase T2 loss-of-function mutations have been reported in infants affected by cystic 
leukoencephalopathy, an autosomal recessive disorder. Although the pathogenic trigger of this RNase 
T2-deficient disease is still unclear, it has emerged that brain magnetic resonance images of affected 
patients are very similar to those of children suffering from intrauterine cytomegalovirus (CMV) 
infection. It is known that to counteract cellular antiviral mechanisms, CMV inactivates the 
endoribonuclease RNase L, which stops the infection by viral mRNA and rRNA degradation. RNase 
T2 might play a similar role in cellular immune response processes51,52. 
Recently, a group of patients affected by a genetic encephalopathy characterised by pediatric onset 
and cerebral calcification, clinically diagnosed as AGS, carry a biallelic loss of function mutations in 
the RNase T2 gene (Table 2). It is still unclear whether these patients belong to AGS cases or not and 
which can be the molecular role of RNase T2 in that pathology53. 
 
 
   Table 2: AGS diagnostic criteria53. 
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Retroelements and DNA damage in AGS 
 
Strong evidence suggests that for the AGS pathogenesis, the accumulation of nucleic acids is 
responsible for triggering the activation of immunity sensors, inducing the increase of CSF IFNα 
levels. As mentioned before, the nucleic acid species accumulated in the cytoplasm of AGS patients 
are yet to be defined. Currently, there are two main hypotheses:  these accumulated nucleic acids can 
be derived by retroelements mobility, as LINE 1, or by DNA damage repair products. Indeed, both 
L1 intermediates and DDR can activate the innate immunity1,4,6,7. Furthermore, these two different 
pathways are interconnected to each other, L1 can induce double-strand breaks (DSBs) on DNA target 
by L1 endonuclease activity and there is evidence that some Nucleotide Excision Repair (NER), and 
DSB repair proteins regulate L1 mobility54. 
 
Transposable elements 
 
Mobile DNAs, also known as transposons or “jumping genes”, are repetitive mobile sequences 
widespread in nature and comprise 45% of the human genome. Transposable elements (TEs) are 
divided into two general classes based on their transposition intermediate: DNA for transposons and 
RNA for retrotransposons55 (Figure 6).  
DNA transposons 
DNA transposons are mobile DNA sequences that move in the genome utilizing a single or double-
stranded DNA as intermediate. Eukaryotic DNA transposons can be divided into three major 
subclasses: those that use a dsDNA as intermediate, the classic “cut and paste” transposons; those 
that use a related rolling-circle replication mechanism, the Helitrons; and finally, Mavericks 
transposons that replicate themselves through a self-encoded DNA polymerase. Both Helitrons and 
Mavericks mobility implicate the displacement and replication of an ssDNA intermediate, 
respectively, through a replicative, copy and paste process. All cut-and-paste transposons are 
characterized by a transposase encoded by autonomous copies and by the presence of terminal 
inverted repeats (TIRs). Retrotransposons dominate the human TE landscape, nonetheless, DNA 
transposons constitute about 3% of the human genome. Generally, there are no known active 
transposons in mammals56. 
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Retrotransposons 
Retrotransposons are subdivided into those sequences that contain Long Terminal Repeats (LTR) and 
those that do not (non-LTR). Both move by a “copy and paste” mechanism: the original transposon 
is maintained in situ, where it is transcribed; its RNA transcript is then reverse transcribed into DNA, 
which integrates into a new genomic location55. 
LTR Retrotransposons 
LTR retrotransposons are relics of ancient retroviruses that once integrated into the germline and then 
lost their ability to infect other cells. Their genomic organization and replication cycle resemble that 
of infectious retroviruses like HIV, with reverse transcription of the viral mRNA primed by a specific 
cellular tRNA. LTR retrotransposons make up about 8% of the human genome, but no active LTR 
retrotransposon has been isolated. However, some intracisternal A-particle (IAP) and Etn/MusD 
family of LTR elements remain active in mice. Ty1/3 elements in yeast and the copia retrotransposons 
of Drosophila melanogaster are examples of active LTR retrotransposons in other species. A 
retrovirus that loses the function of its envelope (env) gene can become an LTR element. Conversely, 
an LTR retrotransposon that acquires an env gene could become a retrovirus. In humans, the closest 
elements to LTR retrotransposons are endogenous retroviruses (HERVs), which represent 7% of the 
genome. Most HERVs have accumulated several nonsense mutations, and no replication-competent 
HERVs are known. The HERV family that is most likely to be functional is the HERVK. However, 
many HERVs and their LTRs, through non-homologous recombination, can be expressed and may 
act as transcriptional regulatory elements for genes55,57,58. 
Non-LTR Retrotransposons 
Non-long terminal repeat (LTR) retroposons are widespread in eukaryotic genomes. Non-LTR 
retrotransposons comprise a significant fraction, 15-17%, of human genomic DNA. Long interspersed 
elements (LINEs or L1s) and short interspersed elements (SINEs) comprise most of this group in 
mammals.  
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L1 elements are the most active autonomous transposable elements in humans, and a substantial 
fraction of the genome, more than 30%, is derived directly or indirectly from its retrotransposition 
activity. Despite the presence of more than 500,000 copies in the human genome, most L1s, due to 
point mutations, rearrangements, or truncations, no longer “jump”, and only an estimated 80-100 
elements remain currently active in any individual diploid human genome. L1 elements preferentially 
retrotranspose the RNA from which they were translated, a phenomenon termed cis preference. 
Although, this propensity for L1 to mobilize itself, other RNAs, such as Alu retroelements, SVAs, 
and other cellular transcripts are commonly retrotransposed by L1.  
Alu elements are about 300 base pairs long and are therefore classified as short interspersed nuclear 
elements (SINEs). Alus are the most abundant and currently most active retrotransposon in humans 
with more than 1 million copies. They are 300bp Pol III RNAs that contain: an internal A and B box, 
an A-rich region that separates the left monomer from the right monomer, and a polyA tail. Alu 
elements, and SINEs in general, are non-autonomous retrotransposons that rely on LINE1-encoded 
proteins to catalyse their retrotransposition55,59.  
 
 
Figure 6: Types of transposable elements in Mammals. (Adapted from John L. Goodier, 2016) 
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Retrotransposition mechanism of L1 elements 
 
The 6 kilobases bicistronic human L1 has a 5' untranslated region (UTR) that functions as an internal 
promoter, a 3' UTR that ends in a poly (A) tail, and two open reading frames (ORF1 and ORF2) on 
the sense strand. A weak L1 promoter on the antisense strand of the 5'UTR lies upstream of a recently 
identified 216-nt ORF0. ORF1 is a 40 kDa RNA-binding protein that forms trimers. ORF1p possesses 
chaperone activity in vitro, and although it is essential for L1 retrotransposition, its precise function 
remains unclear. ORF2 is a 149 kDa protein with endonuclease (EN) and reverse transcriptase (RT) 
activities. The L1 replication cycle starts with the synthesis of a bicistronic mRNA coding the ORF1 
and ORF2 L1 proteins. ORF1p and ORF2p bind the L1 RNA and form a stable ribonucleoprotein 
particle (RNP) (Figure 7).  
 
 
 
Figure 7: L1 life cycle59. 
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This L1 RNP can mediate two different integration 
processes. In the canonical pathway, called target- 
primed reverse transcription (TPRT), ORF2p, with 
its endonuclease activity, nicks the chromosomal 
DNA at a 5′-TTTTA-3′ target site and then extends 
this liberated 3′-OH group, using the L1 RNA as a 
template. In an alternative pathway, the 
endonuclease-independent (ENi) retrotransposition 
or non-classical L1 insertion (NCLI) one, reverse 
transcription starts from a pre-existing DNA lesion, 
without the need of an endonuclease nick. An 
example of this second mechanism of L1 
retrotransposition occurs at telomeres, the natural 
extremity of chromosomes55,60 (Figure 8).  
 
 
 
 
 
 
 
Figure 8: Target-primed reverse transcription (TPRT)57. 
 
L1 impact on the human genome 
 
The first reported identification of an L1 insertion was in 1988, when Haig Kazazian and colleagues, 
studying a patient with hemophilia A, observed a new exonic L1 insertion in the X-linked gene factor 
VIII, where the next generation can inherit this genetic information. Since then, examples of human 
genetic disorders caused by de novo L1 insertions continue to accumulate, and more than 100 cases 
have been shown to trigger heritable diseases, such as: haemophilia, β-thalassaemia, Duchenne 
muscular dystrophy, cystic fibrosis, Apert syndrome, neurofibromatosis and cancer.  
However, recent research has determined that L1 retrotransposition is not only limited to the 
germline. L1 expression and activity have been observed in several human tumours and in some 
tissues of the brain, suggesting that somatic retrotransposition is more frequent than previously 
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expected. Intriguingly, a new L1 insertion can not only be mutagenic by disrupting a coding sequence. 
Indeed, L1 insertions can impact the expression of nearby genes by generating: new splice sites, 
alternative promoters, adenylation signals, and transcription factor-binding sites. L1s can also 
contribute to genetic instability by generating target site deletions, insertions of flanking DNA (target 
site duplication sequences, TSD), recombination with other retrotransposons, and the possible 
generation of chromosomal inversions and interchromosomal translocations 61,62 (Figure 9). 
 
 
Figure 9: How L1 retrotransposons can affect the cell. (1) The L1 sense/antisense promoters in the 5’UTR can 
generate new transcription start sites of flanking genes. (2) Splice sites of a L1 copy integrated in an intronic region 
can cause alternative splicing, including a new exon, of a gene transcript. (3) L1 can alter the chromatin state, 
altering gene expression. (4) L1 reverse transcriptase can mobilize SINE retroelements and other mRNAs, leading 
to further genome expansion. (5) L1 reverse transcriptase switching from L1 RNA to other sequences, such as U6 
or Alu RNAs, create chimeric insertions in the genome (Adapted from Goodier, J. L. & Kazazian, H. H, 2008).  
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Host defense mechanisms against LINE1 retrotransposition 
 
Because of the high potential impact on cellular processes of L1, cells have developed several 
repressive mechanisms or checkpoints to inhibit L1 expression and retrotransposition. These 
repressive mechanisms differ depending on whether the cell is a germ or somatic one.  
L1 is normally silenced in somatic cells in different ways. L1 epigenetic repression involves DNA 
hypermethylation, H3K9me3 and H3K27me3, and recruitment of NuRD repressive complex leading 
to the formation of heterochromatin at the L1 5’ UTR promoter. When L1 is transcribed, its mRNA 
is deaminated and so targeted for degradation by the APOBEC family. L1 mRNA can also be targeted 
for degradation by piRNAs and miRNAs. Then L1 mRNA and proteins can be sequestered into stress 
granules to prevent L1 RNP entering into the nucleus. If L1 RNP crosses the nuclear envelope, there 
are a series of host inhibitory mechanisms to prevent L1 integration. During L1 reverse transcription, 
ERCC1/XPF complex, involved in NER process, can recognizes and remove L1 cDNA to restore the 
original target DNA sequence. Moreover, TREX1 binds and prevents the accumulation of L1 ssDNA 
transcribed by ORF2. Finally, phosphorylation of L1 ORF1 is required for retrotransposition, but the 
L1 life cycle step affected is still not clear. 
L1 is predominately expressed in the germline, but in a controlled manner to maintain genomic 
integrity through each generation. Germline regulation uses L1’s RNAs produced by the bidirectional 
promoter. Sense and antisense L1 RNAs can bind to each other to form dsRNAs, which can be cut 
by dicer into small fragments known as endo-siRNAs. Endo-siRNAs then degrade L1 mRNA through 
RNA interference. Another kind of L1 inhibition in germ cells involves the noncoding PIWI-
interacting RNAs (piRNAs). These piRNAs inhibit L1 in germ cells through four mechanisms: RNA 
degradation, translational inhibition, DNA methylation, and histone modification.   
These inhibitory mechanisms that protect healthy somatic and germ cells from the damaging effects 
of L1 are not all present in every cell and vary by cell type and embryonic origin63. 
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Results 
 
Over 50% of AGS cases carry a mutation in one of the three subunits of the RNase H2 complex. This 
heterotrimeric enzyme is conserved in all eukaryotes representing the major source of ribonuclease 
H activity in mammalian cells. RNase H2 plays several roles in mammalian cells: it removes 
ribonucleotides embedded in chromosomal DNA, it processes Okazaki fragments during DNA 
replication, it disrupts R-loops formed during replication and transcription collisions, and it removes 
RNA:DNA hybrids at telomeres 21,23,24,25,26.  The molecular mechanisms linking RNase H2 mutations 
with the AGS phenotype have not been elucidated yet.  
 
 
Figure 1: RNase H2 inhibition of L1 mobility shown in L1 luciferase retrotransposition assay. (A) A schematic 
drawing the L1 construct and of the Dual-Luciferase retrotransposition assay. A firefly luciferase (Fluc) gene is 
disrupted by an intronic sequence and inserted in the 3’UTR of L1 in anti-sense orientation respect to the L1 gene. 
A Renilla luciferase (Rluc) cassette is inserted in the backbone to allow the normalization. (B) L1 retrotransposition 
assay using L1-Fluc cassette is performed in HeLa cells transduced with RNase H2 shRNAs. Data are reported as 
the ratio between Fluc and Rluc signals and presented as the mean ± SD of three independent experiments. NS, 
not significant; *P ≤ 0.05, **P ≤ 0.01. (C) The efficiency of RNase H2 silencing was monitored by immunoblotting. 
The silencing of an RNase H2 subunit affects the protein level of other subunits.  
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Among all the AGS-causing genes, TREX1, ADAR1, and SAMHD1 have been shown to affect the 
correct metabolism of LINE1 retroelements, DNA sequences able to move in the genome through an 
RNA intermediate18,20,37,47. These findings provide a possible link between the dysregulation of 
retroelemets and the pathogenesis of AGS. Indeed, the nucleic acid species accumulated in the 
cytoplasm as a consequence of a mutation in AGS-causing genes are yet to be defined, and one of the 
major candidates is retrotransposition intermediates. 
To test the possible involvement of endogenous retrotransposons in causing AGS, I used L1 
retrotransposition assays to determine the effects of down-regulation of endogenous RNase H2 
expression on the activity of engineered L1 retrotransposons64,65,66 (Figure 1).  
To knockdown RNase H2 expression, I transfected lentiviral constructs expressing specific short 
hairpin RNAs (shRNAs) into HEK293T cells, where lentiviruses were generated. I employed 
constructs specific for the B and C subunits of RNase H2. Then, I transduced the viruses collected 
from HEK293T cells into either HeLa or fibroblast MRC5 cells. Cells infected with RNase H2 
shRNAs showed a reduction of the levels of RNase H2 subunits as compared to levels in cells infected 
with a plasmid expressing a scrambled shRNA lentiviral vector (negative control) by Western Blot 
(Figure 1C).  
To test the effect of RNase H2 depletion on L1 retrotransposition, I employed a dual-luciferase 
retrotransposition assay using the pYX014 plasmid66. This plasmid carries an engineered L1 element 
that harbours the Firefly luciferase (Fluc) gene as a retrotransposition indicator. The Fluc reporter 
gene was cloned in the antisense orientation (relative to L1) in the 3’UTR of an L1 element, and an 
intron disrupted its coding sequence an L1 element and its coding sequence in the sense orientation 
(Figure 1A). Therefore, Fluc expression occurs in the transfected cells only after one round of 
retrotransposition. In particular, when L1 is transcribed, the intron is removed by splicing, and reverse 
transcription and integration are followed by the transcription of the intact Fluc gene. The resulting 
Firefly luciferase measurement serves as a read-out of L1 retrotransposition efficiency. A Renilla 
Luciferase expression cassette cloned in the backbone of the pYX014 plasmid has been used to 
normalize transfection efficiency. 
I infected HeLa or MRC5 cells with anti-RNase H2 shRNA lentiviral constructs, and after 72 hours, 
I further transfected them with the pYX014 plasmid. Four days after pYX014 transfection, cells were 
lysed for luminescence analysis and L1 activity was measured by Fluc/Rluc ratio (L1 
retrotransposition events/transfection efficiency). Our results showed that, in the absence of RNase 
H2, mobility of L1 is about 4-fold increase compared to the control (scramble shRNA). To confirm 
that the Fluc signal was originated from L1 retrotransposition, I performed these experiments by using 
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in parallel, as a negative control, the pYX015 vector: a construct that presents a missense mutation in 
the L1 ORF1 coding sequence that dramatically impairs L1 retrotransposition66 (Figure 1B).  
To further validate these preliminary data, I also employed a different pJM101/L1.3 retrotransposition 
cassette65. This cassette is similar to pYX014 described above, but the retrotransposition indicator 
Fluc gene is substituted by the neomycin phosphotransferase gene (neor) (Figure 2A). I measured the 
retrotransposition efficiency by counting the number of G418 (neomycin) resistant cells as a result of 
new L1 insertions. 
 
Figure 2: Suppression of L1 mobility by RNase H2 shown in the L1 colony retrotransposition assay. (A) A 
schematic drawing of the L1 construct and the colony retrotransposition assay. A neomycin phosphotransferase 
gene (neor), instead of Fluc one, is disrupted by an intronic sequence and inserted in the 3’ UTR of L1 in an anti-
sense orientation. Retrotransposition of this L1 element confers G418 (neomycin) resistance to host cells. (B) L1 
assays were carried out transfecting HeLa RNase H2 silenced cells or not with this L1 retrotransposition construct 
and selecting for up of 14 days only G418 resistant cells. Representative culture dishes for each condition are 
shown. (C) The efficiency of RNase H2 silencing was tested in a Western Blot analysis. (D) L1 retrotransposition 
assays performed in RNase H2 depleted HeLa cells. In this graph, the colonies indicating L1 retrotransposition 
events, in RNase H2 silenced cells or not, are normalised on the positive control colonies, cells transfected with a 
plasmid that harbour a G418 resistant cassette. Data are shown as the mean ± SD of a single experiment with three 
replicates. NS, not significant; *P ≤ 0.05, **P ≤ 0.01. 
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In particular, by using an experimental protocol similar to the one described above, I infected cells 
first with the anti-RNase H2 shRNA plasmids or control plasmid, and, after 72 hours, I transfected 
them with the pJM101/L1.3 vector. Seventy-two hours later, cells were grown in media supplemented 
with G418 and after about 10 days in G418 selection, the remaining cells were fixed and stained with 
crystal violet to facilitate the visualization and allow the counting of the colonies formed, indicative 
of individual retrotransposition events (Figure 2B). 
To confirm that the results obtained were due to the reduction of RNase H2 expression acting 
specifically on L1 retrotransposition, I carried out these experiments by using the following controls. 
A pcDNA3 plasmid that confers resistance to neomycin to the transfected cells without the need of 
retrotransposition was employed; the resistant colonies were thus indicative of the transfection 
efficiency. Moreover, I employed, as a negative control, the pJM105/L1.3 cassette, identical to 
pJM101/L1.3, but containing a missense mutation in the RT domain of the ORF2 gene that 
dramatically reduces L1 retrotransposition efficiency. Even in this assay, the knockdown of RNase 
H2 expression in HeLa or MRC5 cells induced increased L1 retrotransposition efficiency, as 
compared to scramble shRNA infected cells (Figure 2D).  
Figure 3: RNase H2 inhibits L1 mobility shown in an infection-independent manner. (A), (B) Dual-luciferase L1 
retrotransposition assays performed in HeLa and MRC5 cells respectively, using siRNA against RNase H2 instead 
of lentiviral construct carrying shRNAs. Data are reported as the ratio between Fluc and Rluc signals and 
presented as the mean ± SD of three independent experiments. NS, not significant; *P ≤ 0.05, **P ≤ 0.01. (C) 
Western Blot analysis of RNase H2 silencing in HeLa and MRC5 cells. 
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To exclude any infection-dependent effect on L1 mobility levels in the previous assays, I performed 
luciferase retrotransposition assays in HeLa and MRC5 cells transfected with siRNAs against RNase 
H2. As shown in Figure 3, also in this case, in the absence of RNase H2, L1 mobility increases. Since 
similar results were obtained from retrotransposition assays in RNase H2 depleted cells through 
infection or transfection, we can exclude an infection-dependent impact on L1 retrotransposition, 
confirming the involvement of RNase H2 in L1 regulation. 
To confirm the specificity of the RNase H2 knockdown experiments, I complemented silenced cells 
with a corresponding shRNA-resistant subunit in the context of retrotransposition assays. In 
particular, cells infected with a shRNA against RNase H2B subunit were transfected with H2A, H2C, 
and a shRNA-resistant H2B subunit (H2Br) (Figure 4A). As shown in figure 4B, the resistant form 
of RNase H2B was successfully expressed in RNase H2 silenced cells and partially suppressed the 
increased retrotransposition observed when RNase H2 is knocked down (Figure 4C). These results 
confirm the involvement of RNase H2 in modulating L1 retrotransposition. 
 
 
Figure 4: RNase H2 complementation in L1 retrotransposition assays. (A) Schematic representation of RNase H2 
shRNA-resistant rescue strategy. (B) The efficiency of RNase H2 silencing and complementation was monitored 
by Western Blot analysis. (C) L1 retrotransposition assays performed in RNase H2 depleted or complemented 
HeLa cells. In this graph, L1 retrotransposition efficiency is normalised on shSCR cells one. Data are reported as 
the ratio between Fluc and Rluc signals, normalised on shSCR, and presented as the mean ± SD of three 
independent experiments. NS, not significant; *P ≤ 0.05, **P ≤ 0.01. 
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During the first two years of my PhD, other groups published conflicting results concerning RNase 
H2 and L1 mobility. In particular, Choi et al., using an shRNA strategy, concluded that RNase H2 
inhibits L1 mobility29, similarly to what we observe. On the other hand, Benitez-Guijarro et al., 
studying RNase H2 KO clones, reported that in the absence of RNase H2, L1 mobility decreases30.  
To try to address these contrasting observations, we decided to change our approach and start to 
evaluate RNase H2 involvement in endogenous L1 regulation. First of all, we wanted to verify 
whether RNase H2 has an impact on the number of L1 copies integrated into the genome. To measure 
these little differences of highly repetitive genomic L1s, I used a qPCR approach67. Briefly, I used in 
the same qPCR reaction a Taqman probe designed against L1 ORF2, conjugated with the FAM 
fluorophore, and as control, one conjugated with the VIC fluorophore and designed against α satellite 
sequences, repetitive non-coding DNA of the centromeric heterochromatin. In this way, I analysed 
L1 copy number variations (L1 CNVs), in genomic preparation extracted from RNase H2-silenced 
fibroblasts or control ones (Figure 5B). The same approach has been used with RNase H2B mutated 
primary fibroblasts and control fibroblasts (Figure 5C). This analysis revealed that RNase H2 
silenced/mutated cells, host a lower number of copies of L1 elements compared to controls (Figure 
5B, C).  
Figure 5: L1 number of copies decreases in RNase H2 silenced or mutated fibroblasts. (A) A Schematic draw of 
the L1 CNVs analysis through qRT PCR using probes against L1 ORF2 and SATA repetitive sequences to 
normalise. (B), (C) L1 CNVs analysis of RNase H2 silenced MRC5 or primary mutated fibroblasts, respectively. 
Each experimental condition is represented by six biological replicates and analysed through at least six technical 
replicates, and the data in the graphs are shown as the mean ± SD. NS, not significant; *P ≤ 0.05, **P ≤ 0.01. 
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Then, we evaluated how RNase H2 affects endogenous L1 expression levels by qRT PCR. To this 
aim, we employed MRC5 fibroblasts where RNase H2 was silenced with shRNAs, and primary 
fibroblasts from AGS patients carrying a mutation in RNaseH2. As shown in Figure 6A, when I 
silenced RNase H2, I observed an increase in both L1 5’UTR and ORF2 (L1 N-terminal portion) 
expression levels compared to non-silenced cells, indicating a full-length L1 mRNA increase in a 
depleted condition. Furthermore, in RNase H2-silenced MRC5 fibroblasts, I observed increased 
levels of INFα that can activate type I IFN-induced signalling leading to the main pathogenic trigger 
of AGS syndrome, the immunity hyperactivation (Figure 6A). I obtained similar expression level 
variations in primary fibroblasts derived from an AGS patient carrying RNase H2B mutation 
compared to normal primary fibroblasts: in mutated cells, L1 and IFNα levels are higher (Figure 6B). 
These results seem to suggest the existence of a negative correlation between RNase H2 levels and 
those of L1 and IFNα.   
Figure 6: L1 and IFNα increased expression levels in RNase H2 silenced or mutated fibroblasts. (A) Expression 
levels analysis of L1 5’UTR, L1 ORF2, and IFNα by qRT PCR in RNase H2 depleted MRC5 fibroblasts. (B) L1 
and IFNα expression levels analysis by qRT PCR in primary fibroblasts derived from an AGS patient carrying a 
point mutation in RNase H2B subunit (A177T) compared to control primary fibroblasts. (A), (B) Data in those 
graphs are presented as the mean ± SD of three biological replicates analysed through technical triplicates. NS, 
not significant; *P ≤ 0.05, **P ≤ 0.01. 
 
Considering that we report increased levels of L1 RNA, but fewer copies of L1 integrated into the 
genome, it is reasonable to speculate that, in cells carrying AGS mutated genes, there must be an 
accumulation of L1 intermediates in the cytoplasm.  
I then started to study a possible correlation between loss of RNase H2 genes functions, L1 RNA 
levels, and cytoplasmatic accumulation of nucleic acids.  
In order to modulate L1 mRNA levels, I tested different technical approaches to silence L1, and 
finally, I opted for a combination of siRNAs (Figure 7A). As shown in the graph of Figure 7A, in 
RNase H2-silenced MRC5, L1 and IFNα levels increase compared to control cells (shSCR), but when 
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I lowered L1 levels, though L1-specific shRNAs, also IFNα levels decreased, suggesting a link 
between these two phenotypes. To look for cytoplasmic nucleic acids, I started to analyse the presence 
of ssDNA by immunofluorescence. The data reported in Figure 7B, C, show that in RNase H2-
depleted cells, there is a higher content of ssDNA signal compared to control cells, which is 
suppressed by silencing also L1 (Figures 7B, C).  
 
Figure 7: L1 silencing effects on IFNα levels and ssDNA accumulation in RNase H2 depleted cells. (A) L1 and IFNα 
expression levels analysis by qRT PCR in RNase H2 +/- L1 siRNAs depleted MRC5 compared to shSCR_siLuc 
cells. (B), (C) Representative images of ssDNA immunofluorescence and relative quantification (automated 
analysis with ImageJ software) of mainly cytoplasmatic ssDNA puncta in single MRC5 cells. Statistical significance 
was determined by two-tailed Student’s t-test with the p-values indicated in the graph. 
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We then extended the studies on endogenous L1 to other AGS-causing genes to investigate whether 
the phenotypes observed in RNase H2-depleted cells are general characteristics of AGS patients. In 
other words, we wanted to verify if loss of the nucleic acid metabolizing enzymes in AGS patients 
leads to the dysregulation of L1 mobility, which may be, at least in part, responsible for the 
pathogenesis. ADAR1 and TREX1 have been reported to inhibit the mobility of an exogenous L1 
construct18,20,47. 
First of all, I analysed L1 copy number variations in the genome of ADAR1-silenced MRC5 cells and 
TREX1 mutated primary fibroblasts. As reported in Figure 8, the number of integrated L1 copies is 
lower in ADAR1-silenced cells or TREX1 mutated fibroblasts derived from an AGS patient. It is not 
clear why the results reported in the literature, using retrotransposition assays via an L1 artificial 
exogenous construct, are contrasting with the results obtained with these endogenous LINE1 
analyses. It can be possible that L1 retrotranspostition assays are influenced by an upstream 
transcriptional regulation.  
 
 
Figure 8: L1 number of copies decreases in ADAR1 silenced MRC5 or TREX1 mutated primary fibroblasts. (A) 
L1 CNVs analysis of ADAR1 silenced MRC5 (with shRNA). (B) L1 CNVs analysis of TREX1 primary mutated 
fibroblasts. (A), (B) L1 CNVs analysis through qRT PCR performed using probes against L1 ORF2 and SATA 
repetitive sequences to normalise. Each experimental condition is represented by six biological replicates and 
analysed through at least six technical replicates, and the data in the graphs are shown as the mean ± SD. NS, not 
significant; *P ≤ 0.05, **P ≤ 0.01. 
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I then estimated L1 expression levels in depleted/mutated ADAR1 and TREX1 cells compared to 
controls. As shown in Figure 9, in ADAR1 or TREX1 silenced/mutated cells, L1 expression levels 
are higher compared to control cells. Furthermore, I observed a positive correlation between L1 
expression and IFNα expression levels in depleted conditions again. 
Interestingly, the effects on endogenous L1 are similar for all of these three AGS-related genes, 
suggesting a common thread in AGS pathogenesis.  
 
 
Figure 9: L1 and IFNα increased expression levels in ADAR1 or TREX1 depleted cells. (A) Expression levels 
analysis of L1 5’UTR, L1 ORF2, and IFNα by qRT PCR in MRC5 infected with shRNA against ADAR1. (B) L1 
and IFNα expression levels analysis by qRT PCR in primary fibroblasts derived from an AGS patient carrying a 
point mutation in the TREX1 gene and control primary fibroblasts. (A), (B) Data in the graphs are presented as 
the mean ± SD of three biological replicates analysed through technical triplicates. NS, not significant; *P ≤ 0.05, 
**P ≤ 0.01. 
 
The RNase T2 is the only member of the Rh/T2/S glycoprotein family in humans. Recently, a group 
of infants affected by a genetic encephalopathy with cerebral calcification was reported to carry a 
biallelic loss of function mutations in the RNase T2 gene53. It is still unclear whether these patients 
could be classified as AGS cases or not and what is the molecular role of RNase T2 in that syndrome53. 
To explore the possibility that RNase T2 mutations may be linked to the pathogenesis of AGS, I 
verified, through retrotransposition assays, if this enzyme is be involved in L1 mobility regulation, 
like other AGS related enzymes (Figure 10). Using L1 luciferase retrotransposition assays, I show 
that in RNase T2-silenced cells, L1 mobility increases (Figure 10A), suggesting that this enzyme is 
an L1 retrotransposition inhibitor. 
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Figure 10: RNase T2 inhibition of L1 mobility shown in L1 luciferase retrotransposition assay. (A) A schematic 
drawing of the L1 construct and the Dual-Luciferase retrotransposition assay. (B) L1 retrotransposition assay 
using L1-Luc cassette is performed in MRC5 cells transduced with RNase T2 shRNA. Data are reported as the 
ratio between Fluc and Rluc signals and presented as the mean ± SD of three independent experiments. NS, not 
significant; *P ≤ 0.05, **P ≤ 0.01. (C) The efficiency of RNase T2 silencing was monitored by qRT PCR.  
 
Furthermore, I analysed by qRT PCR whether RNase T2 affects endogenous L1 expression levels. 
As it is shown in figure 11A, in primary fibroblasts carrying an RNase T2 gene mutation, I observed 
an increase of L1 expression levels compared to normal fibroblasts; interestingly, also INFα 
expression levels are elevated in mutated cells, similarly to what observed in the AGS conditions 
described above. Therefore, in these RNase T2 mutated fibroblasts, I can observe a set of phenotypes 
that are likely related to AGS syndrome. 
Finally, we wanted to verify the RNase T2 impact on the number of L1 copies integrated into the 
genome. I analysed genomic preparation extracted from RNase T2 mutated primary fibroblasts or 
control fibroblasts by qRT PCR, using the previously described probes against L1 and the α satellite 
repetitive sequences as normalizer (Figure 11B).  
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In this set of experiments, I did not detect significant differences in L1 copy number between mutated 
fibroblasts and control cells (Figure 11B). These data suggest that RNase T2 may be involved in L1 
regulation in a different way compared to the other AGS-causing genes that we tested. 
 
 
 
Figure 11: L1 endogenous expression levels and genomic CNVs in RNase T2 mutated fibroblasts. (A) Expression 
levels analysis of L1 5’UTR, L1 ORF2, and IFNα by qRT PCR in RNase T2 mutated fibroblasts. (B) qRT PCR L1 
CNVs analysis using probes against L1 ORF2 and SATA repetitive sequences to normalise. Each experimental 
condition is represented by six biological replicates and analysed through at least six technical replicates, and the 
data in the graphs are shown as the mean ± SD. NS, not significant; *P ≤ 0.05, **P ≤ 0.01. 
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Discussion 
 
RNase H2 regulation of LINE1 retroelements 
 
RNase H2 belongs to the family of RNase H enzymes, that process the RNA moiety of RNA:DNA 
hybrids. RNase H2 is a heterotrimeric enzyme conserved in all eukaryotes, and it’s the primary source 
of ribonuclease H activity in mammalian cells. Mutations in each one of the RNase H2 subunits 
account for over 50% of AGS patients, but the molecular mechanisms linking RNase H2 mutations 
to AGS pathology have not been elucidated yet.  
Recent studies from our and other groups have attributed to RNase H2 the role of preserving genome 
integrity by controlling genomic rNTPs incorporation during DNA replication21,24,25,26. RNase H2 
depletion in mice induces massive rNMPs incorporation in the genome, causing p53 dependent 
apoptosis and embryonic lethality4,23,26. Recently, two generated knock-in mice expressing RNase 
H2A, and H2B AGS mutations showed a cCAS-STING dependent interferon signature, similarly to 
the patients27,28.  
Strong evidence suggests that an accumulation of unprocessed, endogenous nucleic acids can trigger 
sensors of the immunity. The nucleic acid species accumulated in the cytoplasm of RNase H2 mutated 
cells are yet to be defined2,5. One speculative model suggests the accumulation of DNA repair by-
products due to genomic rNTPs incorporation 4,27,28.  
Among all the AGS-causing genes, TREX1, ADAR1, and SAMHD1 have been correlated with 
correct metabolism of LINE1(L1) retroelements, the most active autonomous transposable elements 
in human cells, able to move in the genome through an RNA intermediate18,20,37,47. Interestingly, also 
RNase H2 may regulate the mobility of endogenous L1 retroelements by degrading RNA:DNA 
hybrids formed during their replication. Then, another possible source of immunostimulatory nucleic 
acids in RNase H2 deficiency condition can be endogenous retroelements intermediates.  
We decided to focus our efforts on the characterisation of a possible role of RNase H2 as an L1 
retrotransposition regulator. To test this possibility, I used L1 retrotransposition assays to determine 
the effects of RNase H2 down-regulation on the activity of engineered L1 retrotransposons64,65,66. 
Using this assay, RNase H2 activity clearly counteracts L1 mobility (Figures 1,2).  
These results are also reproduced by depleting RNase H2 using a siRNA approach, excluding any 
possible interference caused by adenovirus infection (Figure 3). 
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To further validate these preliminary data, I complemented silenced cells with a corresponding 
shRNA resistant subunit, testing retrotransposition mobility as previously described. As displayed in 
Figure 4, the rescue of RNase H2 expression restricted L1 integration efficiency, suggesting that the 
altered L1 mobility was specifically caused by RNase H2 knockdown. Therefore, considering the 
results obtained from these assays, we speculated that RNase H2 inhibits L1 mobility.  
At the same time, another research group published experiments and results similar to those I 
obtained, RNase H2 knockdown in different human cell lines seems to cause an increase in LINE1 
retrotransposition mobility29. However, the exact mechanism remains far from clear.  
Another group, indeed, published an opposite work showing that RNase H2 has a positive role in L1 
mobility. This group used the same mobility assay described in my thesis but performed on RNase 
H2A KO HeLa cellular clones instead of KD conditions30. Considering that RNase H2 KO induces 
embryonic lethality in mice, we cannot exclude that during clonal selection, the authors could have 
isolated genetic suppressors of RNase H2 activity loss, altering results of retrotransposition assays.  
Since retrotransposition assays used have several critical points, such as L1 over-expression, we 
decided to focus our studies on L1 endogenous regulation.  
First of all, we wanted to analyse L1 copy numbers in the genome of RNase H2 depleted cells to test 
if RNase H2 contributes to maintaining a low rate of endogenous L1 retrotransposition. To perform 
this evaluation, I used a qPCR approach described in Coufal, N. G. et al67. Unexpectedly, I detected 
fewer L1 copies integrated into the genome of RNase H2 silenced/mutated cells compared to controls 
(Figure 5). Although a small decrease in L1 CNVs was observed, it should be considered that L1 
copies constitute about 17% of the human genome, and therefore we are observing a significant 
difference of L1 copies between our experimental conditions, especially in primary fibroblasts. 
This L1 copy number decrease can be due to less L1 integration than the wt. It can also be possible 
that we are observing a case of ORF2-dependent L1 excision. In literature is reported that L1 ORF2 
protein endonuclease activity, usually related to L1 integration, can also be responsible for L1 copies 
excision events68. Moreover, this L1 endogenous phenotype can be a result of recombinogenic events 
between L1 genomic sequences.  
Then, I also estimated endogenous L1 mRNA levels, and in depleted/mutated RNase H2 cells, there 
was a significant increase compared to the controls. It remains to be clarified whether this increase 
depends on a loss of transcriptional repression of L1 elements, or whether the lack of RNase H2 
prevents L1 RNA integration leading to its cytosolic accumulation. An increase of L1 expression 
levels can be consistent with results obtained from retrotrasposition assays and with an L1 inhibitory 
role of RNase H2. On the other hand, if we consider the L1 CNVs analysis, it seems that RNase H2 
promotes L1 integration. It would be possible that RNase H2 regulates multiple steps of the L1 life 
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cycle, inhibiting, at the first step, L1 transcription and at the end, regulating integration of a newly 
synthesized L1 copy in the genome. Indeed, TREX1 provides an example of different levels of L1 
regulation: retroelements can be substrates of this exonuclease, but it is also reported that TREX1 can 
interact with LINE1 ORF1 protein triggering its depletion415,14,20.  
Regarding L1 endogenous phenotypes obtained, increased expression levels, but fewer copies 
integrated into the genome, it could be possible that L1 intermediates are accumulated in the 
cytoplasm of RNase H2 depleted cells. 
In order to correlate a putative L1 intermediates accumulation with cellular production of IFNα, it 
would be useful to modulate L1 endogenous levels. For that reason, I tested different technical 
approaches to silence L1: shRNAs transduction, siRNAs transfection, FANA antisense 
oligonucleotides (FANA ASOs) treatment, and reverse transcription inhibitors (Lamivudine or 3TC) 
treatment. Unfortunately, the depletion of repetitive sequences that represent about 17% of the entire 
genome is quite inefficient. Moreover, in primary fibroblasts, the DNA transfection is impaired. 
The most L1 silencing efficiency was obtained by transfection of a combination of siRNAs or by 
treatment with the reverse transcriptase inhibitor Lamivudine (3TC). 
Then, I began to evaluate if L1 mRNAs levels modulation can trigger IFNα levels variations. From 
preliminary data obtained, in RNase H2 depleted cells, the silencing of L1 also induces decreasing in 
IFNα levels (Figure 7A), suggesting a direct correlation between L1 expression levels and one of the 
key marker of the AGS pathogenesis.   
We wanted to characterise this interesting observed correlation and verify an L1-dependent nucleic 
acids accumulation as a cause of IFNα production. In order to do that, I evaluated by 
immunofluorescence, whether there are differences in the content of ssDNA among: RNase H2 
silenced cells, L1 and RNase H2 silenced cells and control ones. Figure 7 shows that in RNase H2 
depleted cells, there is a higher ssDNA content compared to control cells, and when I silenced L1 in 
those cells, I restore control conditions. Therefore, just lowering L1 expression levels, also ssDNA 
molecules, mainly accumulated in the cytoplasm, decrease, suggesting that some of these nucleic 
acids accumulated in RNase H2 depleted cells derived from L1 retroelements. I will repeat this 
experiment to confirm these promising preliminary data. I will also perform this kind of assay using 
other methods of L1 silencing or reverse transcriptase inhibitors, to try to characterize the precise step 
of RNase H2 involvement in L1 regulation.  
Similar to what observed in RNase H2 mutated cells, also mutations in other AGS genes alter the L1 
number of genomic copies and L1 expression levels. As shown in Figures 8 and 9 in ADAR1 or 
TREX1 silenced/mutated cells, there are fewer L1 copies integrated into the genome and higher L1 
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mRNA levels compared to control cells. Furthermore, high L1 mRNA levels seem to correlate with 
increased IFNα expression (Figure 9).  
However, which DNA intermediates activate the cGAS-STING response remains to be elucidated. 
We observed a strict relation between higher L1 expression and ssDNA accumulation, but what kind 
of immunostimulatory L1 intermediates are accumulated and at what level of L1 retrotransposition 
impairment occurs this accumulation, is still unclear. 
For that reason, we are interested in evaluating the occurrence of L1 intermediates accumulation in 
the cytoplasm of cells carrying AGS mutated genes.  
To further study an L1-dependent nucleic acids accumulation caused by mutation/silencing of AGS 
related genes, I am also setting up, in parallel, an extrachromosomal DNA purification protocol. 
Finally, from these extracts, I obtained only cytoplasmatic DNA without genomic contaminations.  
I am working on the amplification and quantification of L1 sequences content of this purified DNA 
from RNase H2 silenced cells. It would be interesting to sequence these extrachromosomal DNA 
extractions in order to can have a complete analysis of these accumulated nucleic acid species. 
Consisting, it has been recently observed abundant extrachromosomal DNA in human pluripotent 
stem cells lacking TREX1, of which endogenous L1 was a major source17,18.  
It would be interesting to extend these kinds of L1 endogenous evaluations to the others AGS-causing 
genes to demonstrate that the phenotypes observed in RNase H2, ADAR1, or TREX1 depleted 
condition are a general characteristic of AGS patients. We could demonstrate a common 
dysregulation of L1 mobility that can be, at least in part, responsible for the AGS pathogenesis. For 
that reason, we are going to test a complete panel of all the AGS-causing genes depleted cellular lines, 
evaluating the effects on endogenous L1 levels. 
 
RNase T2, a putative AGS-causing gene and its role in L1 mobility 
 
The RNase T2 belongs to the Rh/T2/S glycoprotein family and is specific for single-stranded RNAs. 
Recently, biallelic loss of function in this gene has been reported in a group of infants affected by a 
genetic encephalopathy with cerebral calcification. It is not yet clear whether these patients belong to 
the cases of AGS and what is the molecular role of RNase T2 in that syndrome53. We want to help to 
evaluate if RNase T2 is the eighth AGS-causing gene. I started to verify, through retrotransposition 
assays, if this enzyme could be involved in the regulation of L1 mobility. Similarly to other AGS-
related genes, L1 luciferase retrotransposition assays show that RNase T2 could act as an L1 inhibitor 
(Figure 10).  
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Furthermore, analysing primary fibroblasts carrying RNase T2 mutation, L1 expression increases, 
and similarly to other AGS genes, we observed induced INFα expression (Figure 11A).  
On the other hand, not all phenotypes are similar to RNase H2 because the copy numbers of the 
endogenous L1 seem unaltered compared to the control (Figure 11B). These data suggest that RNase 
T2 could be involved in L1 regulation but differently by other AGS-genes tested. It is of our interest 
to establish if RNase T2 is an AGS causing gene or not and to characterize its role in L1 mobility. 
Further analysis is necessary, but understanding these differences could help us further understand 
the molecular mechanisms that are the cause of AGS. 
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Conclusions and future perspectives 
 
Aicardi-Goutières syndrome is an autoimmune disorder associated with the induction of a type I 
interferon response driven by improper endogenous nucleic acid accumulation6. These nucleic acid 
species accumulated in the cytoplasm of AGS-mutated cells are yet to be defined2,5.  
Among all the AGS-causing genes, TREX1, ADAR1, and SAMHD1 could affect the correct 
metabolism of LINE1 retroelements, the most active autonomous transposable elements in 
humans18,20,37,47.  
Considering RNase H2 enzymatic activities, it can potentially regulate the mobility of endogenous 
L1 retroelements by degrading RNA:DNA hybrids formed during their replication and a possible 
source of immunostimulatory nucleic acids in RNase H2 deficiency condition can be endogenous 
retroelements intermediates. Based on this hypothesis, we decided to start to characterise a possible 
role of RNase H2 as an L1 retrotransposition regulator.  
At the beginning of my PhD project, to test this possible RNase H2 involvement in the L1 mobility 
process, I used L1 retrotransposition assays64,65,66. From these assays, it seemed clear that in RNase 
H2 depleted cellular conditions, mobility of L1 increases. During the first two years of my PhD, 
however, other researcher groups published opposite results concerning RNase H2 role in L1 
mobility29,30. 
Since it is not clear in literature if the RNase H2 enzyme can promote or inhibits L1 mobility, we 
decided to change our approach and start to look at RNase H2 involvement in endogenous L1 
regulation. From these analyses, two phenotypes emerged, an increase of L1 expression levels and 
less L1 copies integrated into the genome of RNase H2 silenced/mutated cells compared to controls.  
We then decided to extend these endogenous L1 evaluations to two known L1 retrotransposition 
inhibitors, ADAR1 and TREX118,20,47. In RNase H2 or ADAR1 or TREX1 silenced cells, I observed 
these phenotypes: 
 higher L1 and IFNα expression levels; 
 less L1 copies integrated into the genome. 
During my PhD, I also started to characterise a role in L1 mobility of the putative AGS-causing gene 
RNase T253. Analysing primary fibroblasts carrying RNase T2 mutation, similarly to other AGS 
genes, we observed an increase of L1 and INFα expression levels (Figure 11A).  
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On the other hand, not all phenotypes are similar to previews described because the L1 genomic copy 
numbers seem unaltered compared to the control (Figure 11B). These data suggest that RNase T2 
could be involved in L1 regulation but in a different way respect to RNase H2, TREX1, and ADAR1. 
In the contest of Aicardi–Goutières syndrome, no one has performed these kinds of endogenous L1 
analysis yet. We think that it is a new approach to study L1 involvement in this pathology, more 
comparable to the condition of patients respect to retrotransposition assays one.  
We want to repeat these kinds of L1 endogenous evaluations considering the other AGS-causing 
genes in order to demonstrate that these L1 phenotypes observed in RNase H2, ADAR1, or TREX1 
depleted condition are a general characteristic of AGS patients.  
It would be really interesting to demonstrate a common correlation between impairment of L1 
regulation and activation of innate immunity in the AGS pathogenesis, especially thinking about 
clinical therapies. 
Whether we and/or other research groups will demonstrate the existence of this common thread 
between the AGS causing genes, it would be also reasonable thinking about a diagnostic test of this 
syndrome. Indeed, it would be possible to analyse L1 endogenous levels, concurrently with AGS 
mutation, to establish a diagnosis before birth.    
Considering both of these observed L1 phenotypes, increased expression levels, but fewer copies 
integrated into the genome are phenotypes consistent with an accumulation of L1 intermediate in the 
cytoplasm of those cells carrying AGS mutated genes. Furthermore, it would be important to 
demonstrate whether this accumulation of nucleic acids derived from L1, or retrotransposons in 
general, is directly linked to the hyperactivation of the innate immunity.  
With this regard, I started to evaluate nucleic acids accumulation in RNase H2 and L1 depleted 
conditions. From this analysis emerges that, just lowering L1 expression levels in RNase H2 silenced 
cells: 
 we can rescue the transcriptional activation of IFNα; 
 ssDNA molecules, accumulated in the cytoplasm of RNase H2 silenced cells, decrease to 
normal condition. 
On the basis of these results, we are on the way to demonstrate that some of these nucleic acids 
accumulated in RNase H2 depleted cells derived from L1 retroelements and the accumulation of these 
L1 intermediates can be relevant for the IFNα overproduction. Indeed, our results showed that the 
selective L1 silencing could have an impact on IFNα expression levels, restoring normal conditions. 
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I will perform this kind of assay using other methods of L1 silencing and in combination with different 
AGS-causing genes depleted conditions, in order to verify a direct link between L1 retroelements and 
the pathogenesis of AGS.   
Besides to demonstrate a pathologic relevance of L1 regulation in the contest of AGS syndrome, we 
are also interested in explaining these observed L1 phenotypes. Starting from the preliminary data 
obtained so far, we propose a model in which: higher L1 expression levels concurrently with less L1 
integration can generate a cytoplasmatic accumulation of DNA retrotransposition intermediates. 
Based on our preliminary data, these L1 cytoplasmatic intermediates, can be in the form of ssDNA 
molecules. However, we can’t exclude that other L1 DNA species, such as dsDNA or RNA:DNA 
hybrids, can be accumulated. In our model, we propose that these L1 intermediates can be 
accumulated in the cytoplasm of AGS patients’ cells by inducing the innate immunity activation 
through the cGAS-STING pathway (Figure 12). 
I still have a lot of work to do in order to understand the molecular mechanisms behind the phenotypes 
observed. Despite this, we hope that our data will be useful in the comprehension of molecular 
processes behind the Aicardi–Goutières pathogenesis and the study of therapies.  
Figure 12: Model of L1 intermediates accumulation effect on AGS pathogenesis. 
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Materials and Methods 
 
Cell culture and transfection 
HeLa, MRC5VI and HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM). 
The complete medium was supplemented with 10% FBS, penicillin, streptomycin and L-glutamine 
and kept at 37ºC in a humidified atmosphere with 5% of CO2. Primary fibroblasts cells derived from 
patients and control cells (48BR) were cultured in DMEM containing 20% FBS, penicillin, 
streptomycin and L-glutamine. Cells were transfected by using lipofectamineRNAiMax or 
lipofectamine3000 (Invitrogen) reagents according to the protocol provided by the manufacturer. 
Lentiviral vectors production 
shRNA sequences were cloned using EcoRI and AgeI restriction enzymes in pLKO.1-TCR cloning 
vector (Addgene). As control, was used SCRAMBLE shRNA cloned in pLKO.1 vector (Addgene). 
Lentiviral vectors were produced by transient co-transfection of pLKO.1 and packaging plasmids 
psPAX2 (Addgene) and pMD2.G (Addgene) in HEK293T cells. Virus was harvested at 48 hours 
post-transfection. Infections of cells were carried out in the presence of 10 mg/ml of polybrene. 
Following transduction, cells were selected adding 1 mg/ml of puromycin to the medium. 
shRNA and siRNA sequences 
siLuc: 5’-CGUACGCGGAAUACUUCGUU-3’ 
siGFP: 5’-GGCUACGUCCAGGAGCGCACCTT-3’  
siRNase_H2B: 5’-GUGGAUAACGUGUUUCCAATT-3’ 
siL1.1: 5’-GGTATCAGCAATGGAAGA-3’ 
siL1.2: 5’-GGAAGATCTACCAAGCCAA-3’ 
shRNase H2A: 5’-CCGTTCTTCCCACCGATATTT-3’ 
shRNase H2B.1: 5′-GCTTCTCCACTACCTCATAAA-3′ 
shRNase H2B.2: 5′-ATCAAACTGTGGCAGCATTAA-3′ 
shADAR1: 5’-GACTGCGAAGGATAGTATATT-3’ 
shRNase T2: 5’-AGATCGTGGCCCTTCAATTTA-3’ 
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L1 retrotransposition assays 
For the L1 Luciferase assay, HeLa or MRC5 cells were seeded in 24-well plates, grow up to 60% of 
confluence and then transduced in triplicate with shRNA lentiviral constructs or alternatively, cells 
were transfected with siRNAs. Seventy-two hours later, cells were further transfected with the 
pYX014 plasmid or the pYX015 one as negative control (the last carries a L1 missense mutation that 
impairs retrotransposition). Four days after transfection, cells were lysed for luminescence analysis 
using the Dual-Luciferase® Reporter Assay System (Promega) and following the manufacturer’s 
instruction. L1 activity was measured as the Fluc/Rluc ratio with the Ensight™ Multimode Plate 
Reader (PerkinElmer). In colony retrotransposition assay, HeLa or MRC5 cells were seeded and 
transduced as described for luciferase assay, but in this case, 72 hours post infection, cells were 
transfected with the pJM101/L1.3 plasmid or positive and negative controls, pcDNA3 vector or 
pJM105/L1.3 cassette respectively. Seventy-two hours later, cells were grown in media supplemented 
with G418 (600 µg/ml) and after about 14 days in G418 selection, the remaining cells were fixed with 
0.4% paraformaldehyde and stained with 0.1% crystal violet to facilitate the visualization and allow 
the counting of the colonies formed (indicative of individual retrotransposition events). Results 
obtained from each experiment were normalized for transfection efficiency. 
Antibodies 
The following antibodies were used: anti-RNase H2A (Abcam, 1:1000), anti-RNase H2B (purified 
from rabbit serum from our lab, 1:500), anti-RNase H2C (Protein-Tech, 1:500), anti-Vinculin (Sigma, 
1:50000). Secondary antibodies were goat anti-mouse or goat anti-rabbit conjugated to HRP (Western 
Blot) or to Alexa Fluor 488 or Alexa Fluor 594 (immunofluorescence). 
Western Blotting 
Cells were lysed in Laemmli sample buffer (60 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100 mM 
DTT), sonicated and boiled for 5 min at 95°C. Equal amounts of whole-cell extracts were analyzed 
by SDS–polyacrylamide gel electrophoresis. Proteins were then transferred to Protran® nitrocellulose 
membrane 0.2 μm (PerkinElmer) by electroblotting or with Trans-Blot® Turbo™ System (BioRad). 
Non-specific antibodies binding was prevented incubating membranes in 5% (w/v) non-fat dry milk 
PBST 0.1% (Blocking buffer) for 1 hour at room temperature. Primary antibodies were diluted in this 
blocking solution and incubated overnight at 4°C. Secondary antibodies were diluted in blocking 
solution and incubated 1 hour at RT. HRP-conjugated secondary antibodies were detected by 
enhanced chemiluminescence (ECL) method, using Clarity™ Western ECL Substrate (BioRad). 
Chemiluminescent filters were imaged with the ChemiDocTouch™ imaging system (BioRad). 
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ssDNA immunofluorescence 
To perform ssDNA staining, MRC5 cells grown on were fixed on ice with 4% PFA for 20 minutes 
and then with methanol at -20°C overnight. The next day, cells were treated with RNase A (200 
μg/mL) at 37°C for 4 hours. Then, the cells were blocked with 3% BSA and incubated overnight at 
4°C with the anti-ssDNA primary antibody (Millipore, MAB3299, 5μg/mL) diluted in 3% BSA. The 
following day, cells were incubated 1 hour at RT with secondary antibody diluted 1:1000 in PBST 
(0,1% Tween). Cells were mounted using ProLong Gold (Invitrogen) containing DAPI to stain nuclei. 
Images were acquired with a Nikon confocal A1 microscope using a ×63 oil immersion objective. 
All microscope settings were set to collect images below saturation and were kept constant for all 
images taken in one experiment. ssDNA puncta quantification for cell was performed using ImageJ. 
Primer sequences 
Primers used in SYBR Green qRT PCR experiments: 
GAPDH_FW: TTGAGGTCAATGAAGGGGTC 
GAPDH_RV: GAAGGTGAAGGTCGGAGTCA 
IFNα_FW: GCCATCTCTGTCCTCCATGA 
IFNα_RV: CTCTCCTCCTGCATCACACA 
RNASET2_FW:  ACTGGCCTGACGTAATTCAC 
RNASET2_RV:  CTTCTTCTGGGAGTTGAGCG 
L1_5’UTR_FW: GCCAAGATGGCCGAATAGGA 
L1_5’UTR_RV: AAATCACCCGTCTTCTGCGT 
L1_ORF2_FW: CAAACACCGCATATTCTCACTCA 
L1_ORF2_RV: CTTCCTGTGTCCATGTGATCTCA 
Primers used in conjunction with TaqMan probes in experiments on genomic DNA:  
L1_ORF2_FW: TGCGGAGAAATAGGAACACTTTT                
L1_ORF2_RV: TGAGGAATCGCCACACTGACT                      
L1_5’UTR_FW: GAATGATTTTGACGAGCTGAGAGAA                         
L1_5’UTR_RV: GTCCTCCCGTAGCTCAGAGTAATT                               
SATA_FW: GGTCAATGGCAGAAAAGGAAAT                 
SATA_RV: CGCAGTTTGTGGGAATGATTC        
 
 
50 
 
qRT-PCR analysis 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). One microgram of RNA 
was used to generate cDNA using iScript™ cDNA Synthesis Kit (Biorad), and 10 ng, or 0,4 ng for 
L1 expression analysis, of cDNA was employed in each qRT PCR assay using the SYBR Green 
system (Genespin). The reactions were performed in triplicate. GAPDH gene was used as the 
normalization control in expression level experiments. For measure of L1 transcription, RNA samples 
were exhaustively digested with RNasefree DNase (Qiagen) before the synthesis of cDNA. 
Effectiveness of the DNase digestion was assessed in -RT PCR controls reactions using RNA 
dilutions instead of cDNA ones. In L1 CNVs evaluations, qRT PCR of genomic DNA was performed 
using the Taqman system (Life Technologies). Genomic DNA was purified with the Phenol-
Chloroform method and 80 pg of gDNA was used with the previews indicated primers and TaqMan 
probes in L1 CNVs qRT PCR experiments. The PCR reactions were performed in at least in triplicate 
in expression levels analysis and at least in six replicates in L1 CNVs ones. CFX Connect Real Time 
System (BioRad) instrument was used for all experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51 
 
Bibliography 
1. Rice, G. et al. Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome. Am. J. 
Hum. Genet. 81, 713–725 (2007). 
2. Crow, Y. J. & Manel, N. Aicardi-Goutières syndrome and the type I interferonopathies. Nat. 
Rev. Immunol. 15, 429–440 (2015). 
3. Stephenson, J. B. P. Aicardi-Goutières syndrome (AGS). Eur. J. Paediatr. Neurol. 12, 355–
358 (2008). 
4. Tolmie, J. L., Shillito, P., Hughes-Benzie, R. & Stephenson, J. B. P. The Aicardi-Goutières 
syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and 
chronic cerebrospinal fluid lymphocytosis). J. Med. Genet. 32, 881–884 (1995). 
5. Crowl, J. T., Gray, E. E., Pestal, K., Volkman, H. E. & Stetson, D. B. Intracellular Nucleic 
Acid Detection in Autoimmunity. Annu. Rev. Immunol. 35, 313–336 (2017). 
6. Chahwan, C. & Chahwan, R. Aicardi-Goutieres syndrome: From patients to genes and 
beyond. Clin. Genet. 81, 413–420 (2012). 
7. Crow, Y. J. et al. Characterization of Human Disease Phenotypes Associated with Mutations 
in TR E X1 , RNAS E H2A ,. Am. J. Med. Genet. Part A 296–312 (2015). 
8. Lee-kirsch, M. A. The Type I Interferonopathies. (2017). doi:10.1146/annurev-med-050715-
104506 
9. Cheng, W. Y. et al. The cGas-sting signaling pathway is required for the innate immune 
response against ectromelia virus. Front. Immunol. 9, (2018). 
10. Ivashkiv, L. B. & Donlin, L. T. Regulation of type i interferon responses. Nature Reviews 
Immunology (2014). doi:10.1038/nri3581 
11. Forster, S. Interferon signatures in immune disorders and disease. Immunol. Cell Biol. 90, 
520–527 (2012). 
12. Crow, Y. J., Vanderver, A., Orcesi, S., Kuijpers, T. W. & Rice, G. I. Therapies in Aicardi-
Goutières syndrome. Clin. Exp. Immunol. 175, 1–8 (2014). 
13. Kavanagh, D. et al. New roles for the major human 3′-5′ exonuclease TREX1 in human 
disease. Cell Cycle (2008). doi:10.4161/cc.7.12.6162 
14. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 Prevents Cell-Intrinsic 
Initiation of Autoimmunity. Cell 134, 587–598 (2008). 
15. Rice, G. I., Rodero, M. P. & Crow, Y. J. Human Disease Phenotypes Associated With 
Mutations in TREX1. Journal of Clinical Immunology (2015). doi:10.1007/s10875-015-
0147-3 
16. Bunney, P. E., Zink, A. N., Holm, A. A., Billington, C. J., & Kotz, C. M. 乳鼠心肌提取 
HHS Public Access. Physiol. Behav. 176, 139–148 (2017). 
17. Bhoj, V. G. & Chen, Z. J. Linking Retroelements to Autoimmunity. Cell 134, 569–571 
(2008). 
52 
 
18. Thomas, C. A. et al. Modeling of TREX1-Dependent Autoimmune Disease using Human 
Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. Cell Stem Cell 
(2017). doi:10.1016/j.stem.2017.07.009 
19. Yang, Y. G., Lindahl, T. & Barnes, D. E. Trex1 Exonuclease Degrades ssDNA to Prevent 
Chronic Checkpoint Activation and Autoimmune Disease. Cell 131, 873–886 (2007). 
20. Li, P. et al. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains 
genome integrity through exonuclease-independent ORF1p depletion. Nucleic Acids Res. 45, 
4619–4631 (2017). 
21. Pizzi, S. et al. Reduction of hRNase H2 activity in Aicardi-Goutières syndrome cells leads to 
replication stress and genome instability. Hum. Mol. Genet. 24, 649–658 (2015). 
22. Holt, I. J. The Jekyll and Hyde character of RNase H1 and its multiple roles in mitochondrial 
DNA metabolism. DNA Repair (2019). doi:10.1016/j.dnarep.2019.06.001 
23. Reijns, M. A. M. et al. Enzymatic removal of ribonucleotides from DNA is essential for 
mammalian genome integrity and development. Cell (2012). doi:10.1016/j.cell.2012.04.011 
24. McElhinny, S. A. N. et al. Genome instability due to ribonucleotide incorporation into DNA. 
Nat. Chem. Biol. (2010). doi:10.1038/nchembio.424 
25. Lazzaro, F. et al. RNase H and postreplication repair protect cells from ribonucleotides 
incorporated in DNA. Mol. Cell (2012). doi:10.1016/j.molcel.2011.12.019 
26. Hiller, B. et al. Mammalian RNase H2 removes ribonucleotides from DNA to maintain 
genome integrity. J. Exp. Med. 209, 1419–1426 (2012). 
27. Mackenzie, K. J. et al. Ribonuclease H2 mutations induce a cGAS/STING‐dependent innate 
immune response. EMBO J. 35, 831–844 (2016). 
28. Pokatayev, V. et al. RNase H2 catalytic core Aicardi-Goutières syndrome-Related mutant 
invokes cGAS-STING innate immunesensing pathway in mice. J. Exp. Med. (2016). 
doi:10.1084/jem.20151464 
29. Choi, J., Hwang, S. Y. & Ahn, K. Interplay between RNASEH2 and MOV10 controls LINE-
1 retrotransposition. Nucleic Acids Res. (2018). doi:10.1093/nar/gkx1312 
30. Benitez‐Guijarro, M. et al. RNase H2, mutated in Aicardi‐Goutières syndrome, promotes 
LINE‐1 retrotransposition. EMBO J. (2018). doi:10.15252/embj.201798506 
31. Beloglazova, N. et al. Nuclease activity of the human SAMHD1 protein implicated in the 
aicardi-goutières syndrome and HIV-1 restriction. J. Biol. Chem. (2013). 
doi:10.1074/jbc.M112.431148 
32. Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the 
SAMHD1 protein. Nature (2011). doi:10.1038/nature10195 
33. Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate 
triphosphohydrolase. Nature (2011). doi:10.1038/nature10623 
34. Lahouassa, H. et al. SAMHD1 restricts the replication of human immunodeficiency virus 
type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat. Immunol. 
(2012). doi:10.1038/ni.2236 
53 
 
35. Rice, G. I. et al. Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as 
regulator of the innate immune response. Nat. Genet. (2009). doi:10.1038/ng.373 
36. Maelfait, J., Bridgeman, A., Benlahrech, A., Cursi, C. & Rehwinkel, J. Restriction by 
SAMHD1 Limits cGAS/STING-Dependent Innate and Adaptive Immune Responses to HIV-
1. Cell Rep. (2016). doi:10.1016/j.celrep.2016.07.002 
37. A., H. et al. The SAMHD1-mediated block of LINE-1 retroelements is regulated by 
phosphorylation. Mob. DNA 9, 11 (2018). 
38. Samhd, A. S. et al. NIH Public Access. 4, 1108–1115 (2014). 
39. Coquel, F., Neumayer, C., Lin, Y. L. & Pasero, P. SAMHD1 and the innate immune 
response to cytosolic DNA during DNA replication. Current Opinion in Immunology (2019). 
doi:10.1016/j.coi.2018.09.017 
40. Coquel, F. et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. 
Nature (2018). doi:10.1038/s41586-018-0050-1 
41. Bass, B. L. RNA Editing by Adenosine Deaminases That Act on RNA. Annu. Rev. Biochem. 
(2002). doi:10.1146/annurev.biochem.71.110601.135501 
42. Rice, G. I. et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a 
type i interferon signature. Nat. Genet. 44, 1243–1248 (2012). 
43. Patterson, J. B. & Samuel, C. E. Expression and regulation by interferon of a double-
stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of 
the deaminase. Mol. Cell. Biol. (1995). doi:10.1128/mcb.15.10.5376 
44. Hartner, J. C., Walkley, C. R., Lu, J. & Orkin, S. H. ADAR1 is essential for the maintenance 
of hematopoiesis and suppression of interferon signaling. Nat. Immunol. (2009). 
doi:10.1038/ni.1680 
45. Pestal, K. et al. Isoforms of RNA-Editing Enzyme ADAR1 Independently Control Nucleic 
Acid Sensor MDA5-Driven Autoimmunity and Multi-organ Development. Immunity (2015). 
doi:10.1016/j.immuni.2015.11.001 
46. Liddicoat, B. J. et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous 
dsRNA as nonself. Science (80-. ). (2015). doi:10.1126/science.aac7049 
47. Orecchini, E. et al. ADAR1 restricts LINE-1 retrotransposition. Nucleic Acids Res. 45, 155–
168 (2017). 
48. Dewannieux, M., Esnault, C. & Heidmann, T. LINE-mediated retrotransposition of marked 
Alu sequences. Nat. Genet. 35, 41–48 (2003). 
49. Rice, G. I. et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease 
phenotypes associated with upregulated type i interferon signaling. Nat. Genet. (2014). 
doi:10.1038/ng.2933 
50. Acquati, F. et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically 
conserved RNase, plays a crucial role in ovarian tumorigenesis. Proc. Natl. Acad. Sci. U. S. 
A. (2013). doi:10.1073/pnas.1222079110 
51. Thorn, A. et al. Structure and activity of the only human RNase T2. Nucleic Acids Res. 
54 
 
(2012). doi:10.1093/nar/gks614 
52. Henneke, M. et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital 
cytomegalovirus brain infection. Nat. Genet. (2009). doi:10.1038/ng.398 
53. Tonduti, D. et al. Encephalopathies with intracranial calcification in children: Clinical and 
genetic characterization. Orphanet J. Rare Dis. (2018). doi:10.1186/s13023-018-0854-y 
54. Ariumi, Y. Guardian of the human genome: Host defense mechanisms against LINE-1 
retrotransposition. Frontiers in Chemistry (2016). doi:10.3389/fchem.2016.00028 
55. Goodier, J. L. Restricting retrotransposons: A review. Mobile DNA (2016). 
doi:10.1186/s13100-016-0070-z 
56. Feschotte, C. & Pritham, E. J. DNA Transposons and the Evolution of Eukaryotic Genomes. 
Annu. Rev. Genet. (2007). doi:10.1146/annurev.genet.40.110405.090448 
57. Volkman, H. E. & Stetson, D. B. The enemy within: Endogenous retroelements and 
autoimmune disease. Nature Immunology (2014). doi:10.1038/ni.2872 
58. Luning Prak, E. T. & Kazazian, H. H. Mobile elements and the human genome. Nature 
Reviews Genetics (2000). doi:10.1038/35038572 
59. Hancks, D. C. & Kazazian, H. H. Active human retrotransposons: Variation and disease. 
Current Opinion in Genetics and Development (2012). doi:10.1016/j.gde.2012.02.006 
60. Viollet, S., Monot, C. & Cristofari, G. L1 retrotransposition: The snap-velcro model and its 
consequences. Mob. Genet. Elements (2014). doi:10.4161/mge.28907 
61. Suarez, N. A., Macia, A. & Muotri, A. R. LINE-1 retrotransposons in healthy and diseased 
human brain. Developmental Neurobiology (2018). doi:10.1002/dneu.22567 
62. Goodier, J. L. & Kazazian, H. H. Retrotransposons Revisited: The Restraint and 
Rehabilitation of Parasites. Cell (2008). doi:10.1016/j.cell.2008.09.022 
63. Khalid, M. et al. Line-1: Implications in the etiology of cancer, clinical applications, and 
pharmacologic targets. Mutation Research - Reviews in Mutation Research (2018). 
doi:10.1016/j.mrrev.2018.09.003 
64. Moran, J. V. et al. High frequency retrotransposition in cultured mammalian cells. Cell 87, 
917–927 (1996). 
65. Doucet, A. J. et al. Characterization of LINE-1 ribonucleoprotein particles. PLoS Genet. 
(2010). doi:10.1371/journal.pgen.1001150 
66. Xie, Y., Rosser, J. M., Thompson, T. L., Boeke, J. D. & An, W. Characterization of L1 
retrotransposition with high-throughput dual-luciferase assays. Nucleic Acids Res. (2011). 
doi:10.1093/nar/gkq1076 
67. Coufal, N. G. et al. L1 retrotransposition in human neural progenitor cells. Nature (2009). 
doi:10.1038/nature08248 
68. Erwin, J. A. et al. L1-associated genomic regions are deleted in somatic cells of the healthy 
human brain. Nat. Neurosci. (2016). doi:10.1038/nn.4388 
 
